Hubbry Logo
logo
Emphysema avatar
Emphysema
Community hub

Emphysema

logo
0 subscribers
Read side by side
Emphysema
View on Wikipedia
from Wikipedia

Emphysema
Advanced centrilobular emphysema showing total lobule involvement on the left side
SpecialtyPulmonology
SymptomsShortness of breath, chronic cough[1]
Usual onsetOver 40 years old[1]
DurationLong term[1]
CausesTobacco smoking, air pollution, genetics[1]
Diagnostic methodSpirometry, Lung Function Test[2]
Differential diagnosisAsthma, congestive heart failure, bronchiectasis, tuberculosis, obliterative bronchiolitis, diffuse panbronchiolitis[3]
PreventionSmoking cessation, improving indoor and outdoor air quality, tobacco control measures[4]
TreatmentPulmonary rehabilitation, long-term oxygen therapy, lung volume reduction[4]
MedicationInhaled bronchodilators and corticosteroids[4]

Emphysema is a condition of the lung marked by abnormal enlargement of the alveoli with loss of pulmonary elasticity.[5] Most commonly, emphysema refers to the permanent enlargement of air spaces (alveoli) in the lungs,[5][6] and is also known as pulmonary emphysema.

Emphysema is a lower respiratory tract disease,[7] characterised by enlarged air-filled spaces in the lungs, that can vary in size and may be very large. The spaces are caused by the breakdown of the walls of the alveoli, which replace the spongy lung tissue. This reduces the total alveolar surface available for gas exchange leading to a reduction in oxygen supply for the blood.[8] Emphysema usually affects the middle aged or older population because it takes time to develop with the effects of tobacco smoking and other risk factors. Alpha-1 antitrypsin deficiency is a genetic risk factor that may lead to the condition presenting earlier.[9]

When associated with significant airflow limitation, emphysema is a major subtype of chronic obstructive pulmonary disease (COPD), a progressive lung disease characterized by long-term breathing problems and poor airflow.[10][11] Without COPD, the finding of emphysema on a CT lung scan still confers a higher mortality risk in tobacco smokers.[12] In 2016 in the United States there were 6,977 deaths from emphysema – 2.2 per 100,000 people.[13] Globally it accounts for 5% of all deaths.[14] A 2018 review of work on the effects of tobacco and cannabis smoking found that a possibly cumulative toxic effect could be a risk factor for developing emphysema and spontaneous pneumothorax.[15][16]

There are four types of emphysema, three of which are related to the anatomy of the lobules of the lung – centrilobular or centriacinar, panlobular or panacinar, and paraseptal or distal acinar emphysema – and are not associated with fibrosis (scarring).[17] The fourth type is known as paracicatricial emphysema or irregular emphysema that involves the acinus irregularly and is associated with fibrosis.[17] Though the different types can be seen on imaging they are not well-defined clinically.[18] There are also a number of associated conditions, including bullous emphysema, focal emphysema, and Ritalin lung. Only the first two types of emphysema – centrilobular and panlobular – are associated with significant airflow obstruction, with that of centrilobular emphysema around 20 times more common than panlobular. Centrilobular emphysema is the only type associated with smoking.[17]

Osteoporosis is often a comorbidity of emphysema. The use of systemic corticosteroids for treating exacerbations is a significant risk factor for osteoporosis, and their repeated use is recommended against.[19]

Signs and symptoms

[edit]
Diagram of alveoli with emphysema

Emphysema is a respiratory disease of the lower respiratory tract.[7] It is commonly caused by tobacco smoking but some people are affected who have never smoked.[14] The presence of emphysema is a clear risk factor for lung cancer, made stronger in those who smoke.[20]

Early symptoms of emphysema vary. They can include a cough (with or without sputum), wheezing, a fast breathing rate, breathlessness on exertion, and a feeling of tightness in the chest. There may be frequent cold or flu infections.[1] Other symptoms may include anxiety, depression, fatigue, sleep problems and weight loss. These symptoms could also relate to other lung conditions or other health problems;[21] therefore, emphysema is often underdiagnosed.[citation needed] The shortness of breath emphysema causes can increase over time and develop into chronic obstructive pulmonary disease.

A sign of emphysema in smokers is a higher number of alveolar macrophages sampled from the bronchoalveolar lavage (BAL) in the lungs. The number can be four to six times greater in those who smoke than in non-smokers.[22]

Emphysema is also associated with barrel chest.

Types

[edit]

There are four main types of emphysema, three of which are related to the anatomy of the lobules of the lung – centrilobular or centriacinar, panlobular or panacinar, and paraseptal or distal acinar and are not associated with fibrosis (scarring).[17] Although fibrosis is not a normal feature of these subtypes, repair strategies in end-stage emphysema may lead to pulmonary fibrosis.[14] The fourth subtype is known as paracicatricial emphysema or irregular emphysema, involves the acinus irregularly and is associated with fibrosis.[17]

Only the first two types of emphysema – centrilobular and panlobular – are associated with significant airflow obstruction, with that of centrilobular emphysema around 20 times more common than panlobular.[17] The subtypes can be seen on imaging but are not well-defined clinically.[18] There are also a number of associated conditions including bullous emphysema, focal emphysema, and Ritalin lung.

Centrilobular

[edit]
Stained lung tissue from end-stage emphysema

Centrilobular emphysema, also called centriacinar emphysema, affects the centre of a pulmonary lobule (centrilobular) in the lung, the area around the terminal bronchiole and the first respiratory bronchiole, and can be seen on imaging as an area around the tip of the visible pulmonary artery. Centrilobular emphysema is the most common type usually associated with smoking, and with chronic bronchitis.[17] The disease progresses from the centrilobular portion, leaving the lung parenchyma in the surrounding (perilobular) region preserved.[23] Usually the upper lobes of the lungs are affected.[17]

Panlobular

[edit]

Panlobular emphysema, also called panacinar emphysema, affects all of the alveoli in a lobule, and can involve the whole lung or mainly the lower lobes.[18][24] This type of emphysema is associated with alpha-1 antitrypsin deficiency (A1AD or AATD), and Ritalin lung,[24] and is not related to smoking.[18]

Complications

[edit]

Likely complications of centrilobular and panlobular emphysema, some of which are life-threatening, include: respiratory failure, pneumonia, respiratory infections, pneumothorax, interstitial emphysema, pulmonary heart disease, and respiratory acidosis.[25]

Paraseptal

[edit]

Paraseptal emphysema, also called distal acinar emphysema, relates to emphysematous change next to a pleural surface, or to a fissure.[18][26] The cystic spaces known as blebs or bullae that form in paraseptal emphysema typically occur in just one layer beneath the pleura. This distinguishes it from the honeycombing of small cystic spaces seen in fibrosis that typically occurs in layers.[26] This type of emphysema is not associated with airflow obstruction.[27]

Bullous

[edit]
CT scan of bullous emphysema

When the subpleural bullae are significant, the emphysema is called bullous emphysema. Bullae can become extensive and combine to form giant bullae. These can be large enough to take up a third of a hemithorax, compress the lung parenchyma, and cause displacement. The emphysema is now termed giant bullous emphysema, more commonly called vanishing lung syndrome due to the compressed parenchyma.[28] A bleb or bulla may sometimes rupture and cause a pneumothorax.[17]

Paracicatricial

[edit]

Paracicatricial emphysema, also known as irregular emphysema, is seen next to areas of fibrosis (scarring) as large spaces. The scarring is most often a result of silicosis, granulomatous infection, tuberculosis, or pulmonary infarction. It can be difficult to differentiate from the honeycombing of pulmonary fibrosis.[29]

HIV associated

[edit]

Classic lung diseases are a complication of HIV/AIDS with emphysema being a source of disease. HIV is cited as a risk factor for the development of emphysema and COPD regardless of smoking status.[30] Around 20 percent of those with HIV have increased emphysematous changes. This has suggested that an underlying mechanism related to HIV is a contributory factor in the development of emphysema. HIV associated emphysema occurs over a much shorter time than that associated with smoking; an earlier presentation is also seen in emphysema caused by alpha-1 antitrypsin deficiency. Both of these conditions predominantly show damage in the lower lungs, which suggests a similarity between the two mechanisms.[31]

[edit]

Emphysema may develop in some people with alpha-1 antitrypsin deficiency, the only genotype of chronic obstructive pulmonary disease. This usually occurs a lot earlier (as does HIV associated emphysema) than other types.[32]

Ritalin lung

[edit]

The intravenous use of methylphenidate, commonly marketed as Ritalin and widely used as a stimulant drug in the treatment of attention deficit hyperactivity disorder, can lead to emphysematous changes known as Ritalin lung. The mechanism underlying this link is not clearly understood. Ritalin tablets are not intended to be injected. They contain talc as a filler, and it has been suggested that talc exposure causes granulomatosis leading to alveolar destruction. However, other intravenous drugs also contain talc, and no emphysematous change is associated with those. High resolution CT scanning shows the emphysema to be panlobular.[33]

CPFE

[edit]

Combined pulmonary fibrosis and emphysema (CPFE) is a rare syndrome that shows upper-lobe emphysema, together with lower-lobe interstitial fibrosis. This is diagnosed by CT scan.[34] This syndrome presents a marked susceptibility for the development of pulmonary hypertension.[35]

SRIF

[edit]

Smoking-related interstitial fibrosis (SRIF) is another type of fibrosis that occurs in emphysematous lungs and can be identified by pathologists. Unlike CPFE, this type of fibrosis is usually clinically occult (i.e., does not cause symptoms or imaging abnormalities). Occasionally, however, some patients with SRIF present with symptoms and radiologic findings of interstitial lung disease.[36]

Congenital lobar

[edit]

Congenital lobar emphysema (CLE), also known as congenital lobar overinflation and infantile lobar emphysema,[37] is a neonatal condition associated with enlarged air spaces in the lungs of newborn infants. It is diagnosed around the time of birth or in the first 6 months of life, occurring more often in boys than girls. CLE affects the upper lung lobes more than the lower lobes, and the left lung more often than the right lung.[38] CLE is defined as the hyperinflation of one or more lobes of the lung due to the partial obstruction of the bronchus. This causes symptoms of pressure on the nearby organs. It is associated with several cardiac abnormalities such as patent ductus arteriosus, atrial septal defect, ventricular septal defect, and tetralogy of Fallot.[39] Although CLE may be caused by the abnormal development of bronchi, or compression of airways by nearby tissues, no cause is identified in half of cases.[38] CT scan of the lungs is useful in assessing the anatomy of the lung lobes and status of the neighbouring lobes on whether they are hypoplastic or not. Contrast-enhanced CT is useful in assessing vascular abnormalities and mediastinal masses.[39]

Focal

[edit]
A large bulla and a smaller bleb illustrated

Focal emphysema is a localized region of emphysema in the lung that is larger than alveoli, and often associated with coalworker's pneumoconiosis.[40] This is also known as localized pulmonary emphysema.[41] Blebs and bullae may also be included as focal emphysema. These can be differentiated from the other type of enclosed air space known as a lung cyst by their size and wall thickness. A bleb or bulla has a wall thickness of less than 1 mm, and are smaller.[42]

Occupational

[edit]

A number of occupations are associated with the development of emphysema due to the inhalation of varied gases and particles. In the US uranium mining that releases radon gas and particles has been shown to be a cause of emphysema deaths; the figures in the study included some miners who also smoked. Uranium mining and milling was found to create environmental pollution.[43]

The inhalation of coal mine dust that can result in coalworker's pneumoconiosis is an independent risk factor for the development of emphysema. Focal emphysema is associated with the coal macule, and this extends into progressive centrilobular emphysema. Less commonly a variant of panlobular emphysema develops.[44]

Silicosis results from the inhalation of silica particles, and the formation of large silica nodules is associated with paracicatricial emphysema, with or without bullae.[45]

Ozone-induced emphysema

[edit]

Ozone is another pollutant that can affect the respiratory system. Long-term exposure to ozone can result in emphysema.[46]

Osteoporosis

[edit]

Osteoporosis is a major comorbidity of emphysema. Both conditions are associated with a low body mass index.[47] There is an association between treating emphysema and osteoporosis; the use of systemic corticosteroids for treating exacerbations is a significant risk factor for osteoporosis, and their repeated use is not recommended.[19]

Other terms

[edit]
Further information: Pneumatosis

Compensatory emphysema is overinflation of part of a lung in response to either removal by surgery of another part of the lung or decreased size of another part of the lung.[48]

Pulmonary interstitial emphysema (PIE) is a collection of air inside the lungs but outside the normal air space of the alveoli, found as pneumatoses inside the connective tissue of the peribronchovascular sheaths, interlobular septa, and visceral pleura.

Lung volume reduction

[edit]

Lung volume reduction may be offered to those with advanced emphysema. When other treatments fail, and the emphysema is in the upper lobes, a surgical option may be possible.[49] A number of minimally invasive bronchoscopic procedures are increasingly used to reduce lung volume.[50]

Surgical

[edit]

Where there is severe emphysema with significant hyperinflation that has proved unresponsive to other therapies, lung volume reduction surgery (LVRS) may be an option.[51][52] LVRS involves the removal of tissue from the lobe most damaged by emphysema, which allows the other lobes to expand and give improved function. The procedure appears to be particularly effective if the emphysema primarily involves the upper lobes; however, the procedure increases the risk of adverse events and early death in people who have diffuse emphysema.[53][49]

Bronchoscopic

[edit]
Further information: Bronchoscopic lung volume reduction

Minimally invasive bronchoscopic procedures may be carried out to reduce lung volume. These include the use of valves, coils, or thermal ablation.[54][55] Endobronchial valves are one-way valves that may be used in those with severe hyperinflation resulting from advanced emphysema; a suitable target lobe and no collateral ventilation are required for this procedure. The placement of one or more valves in the lobe induces a partial collapse of the lobe that ensures a reduction in residual volume that improves lung function, the capacity for exercise, and quality of life.[56]

The placement of endobronchial coils made of nitinol, instead of valves is recommended where there is collateral ventilation that would prevent the use of valves.[57][58] Nitinol is a biocompatible shape-memory alloy.

Both of these techniques are associated with adverse effects, including persistent air leaks and cardiovascular complications. Bronchoscopic thermal vapor ablation has an improved profile. Heated water vapor is used to target affected lobe regions, which leads to permanent fibrosis and volume reduction. The procedure is able to target individual lobe segments, can be carried out regardless of collateral ventilation, and can be repeated with the natural advance of emphysema.[59]

Other surgeries

[edit]

Lung transplantation – the replacement of either a single lung or both (bilateral) – may be considered in end-stage disease. A bilateral transplant is the preferred choice as complications can arise in a remaining single native lung; complications can include hyperinflation, pneumonia, and the development of lung cancer.[60] Careful selection as recommended by the National Emphysema Treatment Trial (NETT) for transplant surgeries is needed as in some cases there will be an increased risk of mortality.[49] Several factors, including age and exercise tolerance using the BODE index need to be taken into account.[60] A transplant is considered only when there are no serious comorbidites.[50] A CT scan or a ventilation/perfusion scan may be useful to evaluate cases for surgical interventions and to evaluate post-surgery responses.[61] A bullectomy may be carried out when a giant bulla occupies more than a third of a hemithorax.[50]

In other tissues

[edit]

Trapped air can also develop in other tissues such as under the skin, known as subcutaneous emphysema. Orbital emphysema is the trapping of air in the orbit; a type of this is palpebral emphysema that affects just the eyelids.[62] Emphysematous gastritis is the presence of air in the stomach wall, usually caused by a bacterial infection.[63] This is rare but has a high mortality rate.[64]

History

[edit]
Giovanni Battista Morgagni, who recorded one of the earliest descriptions of emphysema in 1769

The terms emphysema and chronic bronchitis were formally defined in 1959 at the CIBA guest symposium, and in 1962 at the American Thoracic Society Committee meeting on Diagnostic Standards.[65] The word emphysema is derived from Ancient Greek ἐμφύσημα 'inflation, swelling'[66] (referring to a lung inflated by air-filled spaces), itself from ἐμφυσάω emphysao 'to blow in, to inflate',[67] composed of ἐν en, meaning "in", and φυσᾶ physa,[68] meaning "wind, blast".[69][70]

René Laennec, the physician who invented the stethoscope, used the term emphysema in his book A Treatise on the Diseases of the Chest and of Mediate Auscultation (1837) to describe lungs that did not collapse when he opened the chest during an autopsy.[65] He noted that they did not collapse as usual because they were full of air and the airways were filled with mucus.[65] Early descriptions of probable emphysema include: in 1679 by T. Bonet of a condition of "voluminous lungs" and in 1769 by Giovanni Morgagni of lungs which were "turgid particularly from air".[65][71] In 1721 the first drawings of emphysema were made by Ruysh.[71] These were followed the illustrations of Matthew Baillie in 1789 and descriptions of the destructive nature of the condition.

References

[edit]

Bibliography

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Emphysema

View on Grokipedia
from Grokipedia
Emphysema is a progressive lung disease and a primary form of chronic obstructive pulmonary disease (COPD), characterized by the irreversible destruction of the alveoli—the tiny air sacs in the lungs responsible for gas exchange—resulting in enlarged air spaces, air trapping, and reduced oxygen intake.[1] This damage impairs airflow and leads to persistent respiratory symptoms, making breathing increasingly difficult over time, with no known cure but treatments available to manage progression and symptoms.[2] Globally, emphysema contributes to the burden of COPD, which affects an estimated 392 million people and ranks as the fourth leading cause of death worldwide, causing 3.5 million deaths in 2021.[3] In the United States, more than 3 million individuals live with emphysema, predominantly those with a history of smoking.[4] The primary cause of emphysema is long-term exposure to irritants, with cigarette smoking accounting for 80-90% of cases, typically manifesting symptoms after 20 pack-years of use.[2] Other etiological factors include inhalation of biomass fuel smoke, environmental pollutants, occupational dust and chemicals, secondhand smoke, and rare genetic conditions like alpha-1 antitrypsin (AAT) deficiency, which affects 1-2% of patients and leads to early-onset disease.[1] Pathophysiologically, these exposures trigger an inflammatory response and protease-antiprotease imbalance, destroying alveolar walls and reducing the lung's elastic recoil, which exacerbates airflow limitation.[2] Risk factors are amplified in individuals over age 40, with higher prevalence among white male smokers (14%) compared to nonsmokers (3%).[2] Symptoms of emphysema often develop gradually and include chronic shortness of breath (dyspnea), especially during physical activity, chronic cough with or without mucus production, wheezing, chest tightness, and fatigue.[4] In advanced stages, patients may exhibit pursed-lip breathing, use of accessory respiratory muscles, weight loss, and signs of hyperinflation such as a barrel-shaped chest.[2] Complications can be severe, encompassing pulmonary hypertension, cor pulmonale (right-sided heart failure), bullae formation, spontaneous pneumothorax (collapsed lung), increased lung cancer risk, and associated anxiety or depression.[1] Diagnosis relies on clinical history, physical examination, and confirmatory spirometry showing a post-bronchodilator forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) ratio below 0.70, with severity staged from mild (FEV1 ≥80% predicted) to very severe (<30%).[2] Additional tests may include chest X-rays or CT scans to visualize hyperinflation and bullae, arterial blood gas analysis for oxygenation levels, and AAT screening in younger patients or those without smoking history.[4] Treatment emphasizes smoking cessation as the cornerstone intervention to halt progression, alongside bronchodilators (e.g., beta-2 agonists and anticholinergics), inhaled corticosteroids for exacerbations, pulmonary rehabilitation, oxygen therapy for hypoxemia (PaO2 <55 mmHg), and surgical options like lung volume reduction or transplantation in select severe cases.[2] Preventive measures include vaccinations against influenza and pneumococcus, avoidance of pollutants, and early intervention for at-risk populations.[4]

Overview and Epidemiology

Definition and Characteristics

Emphysema is a pathological condition of the lung characterized by the permanent, abnormal enlargement of airspaces distal to the terminal bronchioles, accompanied by destruction of their walls and without obvious fibrosis.[2] This destruction leads to the coalescence of alveoli into larger, irregular airspaces, reducing the overall surface area available for gas exchange.[2] The core features of emphysema include lung hyperinflation due to air trapping, loss of elastic recoil in the lung tissue, and progressive airflow obstruction during exhalation.[5] These changes result from the degradation of alveolar walls, which normally provide structural support and elasticity to the lungs.[2] Emphysema is a primary pathological component of chronic obstructive pulmonary disease (COPD), where it contributes significantly to airflow limitation and respiratory impairment in affected individuals. However, emphysema can occur without persistent airflow obstruction on spirometry and thus may not meet the clinical diagnostic criteria for COPD.[6][7] Emphysema primarily involves the acinus, the functional unit of the lung that encompasses the respiratory bronchioles, alveolar ducts, and alveoli.[8] Damage within this structure disrupts the normal architecture, leading to inefficient ventilation and impaired oxygen diffusion.[2] In distinction from chronic bronchitis, the other major form of COPD, emphysema does not feature prominent airway inflammation or mucus hypersecretion but instead emphasizes irreversible parenchymal destruction.[6][9]

Prevalence and Distribution

Specific global prevalence estimates for emphysema are limited and often reported within the context of COPD, of which emphysema is a major component; recent data indicate COPD affects over 213 million people worldwide as of 2021, with age-standardized prevalence of about 2,700 per 100,000.[10] Rates are significantly higher among smokers. In the Multi-Ethnic Study of Atherosclerosis (MESA), a general population cohort of adults aged 45-84, 5.4% had emphysema-like lung changes on CT scans exceeding the upper limit of normal.[11] In the United States, over 3 million individuals live with emphysema as of recent estimates, with prevalence increasing with age.[4] Annual incidence rates for emphysema are approximately 1-2% in high-risk groups such as long-term smokers over 40, though specific data are limited and often derived from COPD studies where emphysema is a predominant phenotype.[12] Incidence is rising in developing countries, particularly due to increased exposure to biomass fuel smoke in household settings, which contributes to non-smoking-related cases.[13] The condition predominantly affects individuals over 50 years, with historical disparities showing higher rates in males due to greater smoking prevalence, but rates are equalizing as female smoking patterns decline and male rates fall.[14] In some regions, urban populations experience higher prevalence compared to rural ones, linked to air pollution and occupational exposures.[13] Geographically, prevalence is higher in Europe and North America, reflecting historical high smoking rates. Cases are emerging in Asia alongside rising tobacco use, while in low- and middle-income countries, nearly 90% of related deaths under age 70 occur due to combined tobacco and indoor air pollution risks.[13] Trends indicate a decline in high-income countries following smoking bans and tobacco control since 2000, with reductions observed in places like Sweden.[15]

Pathophysiology

Mechanisms of Tissue Destruction

Emphysema arises from a complex interplay of cellular and biochemical processes that culminate in the irreversible destruction of alveolar walls. Central to this pathogenesis is the disruption of lung structural homeostasis, where inflammatory, proteolytic, oxidative, and apoptotic mechanisms overwhelm repair pathways, leading to airspace enlargement. These processes are primarily triggered by chronic insults such as cigarette smoke, which activates resident immune cells and recruits additional inflammatory mediators to the lung parenchyma.[16] A fundamental mechanism involves the protease-antiprotease imbalance, where proteolytic enzymes degrade the extracellular matrix (ECM) of the alveoli. Neutrophil elastase, released by activated neutrophils, plays a pivotal role by cleaving elastin and other ECM components, while matrix metalloproteinases (MMPs), particularly MMP-9 and MMP-12 from macrophages, further amplify tissue breakdown. This excess proteolysis overwhelms the inhibitory capacity of alpha-1 antitrypsin (A1AT), the primary serine protease inhibitor, which is inactivated by oxidative stress or reduced in concentration during inflammation. In severe cases, genetic A1AT deficiency exacerbates this imbalance, but it occurs broadly in smokers through functional impairment.[17] Oxidative stress contributes significantly by generating reactive oxygen species (ROS) that directly damage lung tissue and perpetuate destructive cycles. Cigarette smoke delivers a massive oxidant burden—approximately 10^15 free radicals per puff—while activated inflammatory cells produce additional ROS, such as superoxide anions and hydrogen peroxide. These ROS inactivate antiproteases like A1AT, enhance protease activity, and induce mitochondrial dysfunction, leading to lipid peroxidation and DNA damage in alveolar cells. The resulting oxidative environment amplifies inflammation and impairs cellular repair, fostering progressive alveolar destruction.[18][19] Inflammation pathways drive the recruitment and activation of immune cells that sustain tissue damage. Neutrophils and macrophages accumulate in the alveolar walls, drawn by chemokines such as IL-8 (CXCL8) and leukotriene B4, leading to a 5- to 10-fold increase in their numbers compared to healthy lungs. These cells release pro-inflammatory cytokines, including TNF-alpha and IL-8, which not only recruit more leukocytes but also stimulate the production of proteases and ROS. Macrophages, in particular, localize to sites of alveolar destruction, secreting MMPs that degrade elastin and collagen, while neutrophils contribute elastase-mediated injury, creating a self-reinforcing inflammatory milieu.[20][21] Apoptosis of alveolar cells represents a critical downstream event in emphysema pathogenesis, where programmed cell death outpaces proliferation, resulting in net loss of septal structures. Type II pneumocytes, responsible for surfactant production and alveolar repair, undergo apoptosis via intrinsic pathways triggered by neutrophil elastase, which activates caspase-9 through reduced AKT phosphorylation, and by ROS-induced p53 activation leading to Bax translocation. Endothelial cells similarly succumb, with decreased VEGF signaling disrupting the PI3K/Akt anti-apoptotic pathway and increasing caspase activity. This dual apoptosis of epithelial and endothelial cells erodes alveolar integrity, enlarging airspaces without effective replacement.[22][23] An imbalance in repair mechanisms further exacerbates destruction by hindering alveolar regeneration. Defective vascular endothelial growth factor (VEGF) signaling, marked by reduced VEGF and VEGFR2 expression in emphysematous lungs, impairs endothelial survival and vascular maintenance, promoting apoptosis and capillary rarefaction. Concurrently, diminished anti-apoptotic factors, such as those modulated by A1AT, fail to counteract caspase-3 activation, while cellular senescence limits proliferative capacity. This repair deficit transforms transient injury into permanent structural loss, underscoring the homeostatic failure in emphysema.[24][25]

Structural and Functional Changes

Emphysema is characterized by the progressive destruction of alveolar septa, leading to the enlargement of airspaces distal to the terminal bronchioles without accompanying fibrosis. This destruction results in a loss of the alveolar walls that normally support the pulmonary capillary bed, reducing the surface area available for gas exchange and contributing to ventilation-perfusion (V/Q) mismatch.[26][27][28] These structural alterations promote lung hyperinflation, marked by an increase in residual volume (RV) and total lung capacity (TLC), often exceeding 120-130% of predicted values, due to air trapping from narrowed and collapsible small airways. The diaphragm becomes flattened as a result of this overexpansion, impairing its contractile efficiency and contributing to respiratory muscle dysfunction. Functionally, the loss of elastic fibers diminishes lung recoil pressure, exacerbating air trapping and leading to dynamic hyperinflation, particularly during physical exertion when expiratory time is limited.[5][2][29] The impaired gas exchange in emphysema primarily manifests as hypoxemia, driven by V/Q mismatch where destroyed alveolar regions receive ventilation but inadequate perfusion, or vice versa, with high V/Q areas predominating in emphysematous lungs. In advanced stages, this can progress to hypercapnia as overall ventilatory capacity declines and alveolar hypoventilation worsens. Pulmonary function tests reflect these changes, with a reduced FEV1/FVC ratio below 70% indicating airflow obstruction, and a decreased diffusing capacity for carbon monoxide (DLCO) due to the diminished alveolar-capillary interface.[30][2][31][32]

Causes and Risk Factors

Tobacco Smoking

Tobacco smoking is the predominant modifiable risk factor for emphysema, accounting for the majority of cases through chronic exposure to inhaled irritants that progressively destroy alveolar structures.[33] Cigarette smoke consists of an aerosol containing over 7,000 chemical compounds, including tar, nicotine, carbon monoxide, and numerous others such as acrolein, formaldehyde, and benzene, many of which are highly reactive and contribute to alveolar wall damage by disrupting cellular repair and promoting fibrosis.[34] These components, particularly the tar phase particulates and gas-phase oxidants, deposit in the lungs and initiate direct toxicity to epithelial cells, leading to impaired gas exchange and structural remodeling characteristic of emphysema.[35] The pathogenic mechanisms involve cigarette smoke particles triggering an intense inflammatory response in the lung parenchyma, where alveolar macrophages and recruited neutrophils release reactive oxygen species (ROS) that overwhelm antioxidant defenses, causing oxidative stress and lipid peroxidation of alveolar membranes.[36] This oxidative burden further amplifies inflammation by activating transcription factors like NF-κB, which upregulate pro-inflammatory cytokines (e.g., TNF-α, IL-8) and stimulate the release of proteases such as neutrophil elastase and matrix metalloproteinases (MMPs) from inflammatory cells.[37] The resulting protease-antiprotease imbalance degrades elastin fibers in the alveolar walls, leading to airspace enlargement and loss of elastic recoil, hallmarks of emphysematous tissue destruction.[38] The risk of developing emphysema exhibits a clear dose-response relationship with cumulative tobacco exposure, measured in pack-years (one pack-year equaling 20 cigarettes per day for one year), with heavier smokers facing exponentially higher odds. For instance, in a study of South Korean adults, women with 20 or more pack-years of smoking history had an odds ratio of approximately 3.9 for chronic obstructive pulmonary disease (COPD), of which emphysema is a key component, compared to never-smokers.[39] Even secondhand smoke exposure elevates risk, with meta-analyses indicating an odds ratio of about 2.25 for COPD in never-smokers exposed to environmental tobacco smoke, particularly through chronic inhalation of similar toxicants at lower concentrations.[40] Electronic cigarettes (e-cigarettes) and vaping products, which deliver nicotine and other aerosols, represent an emerging risk factor related to tobacco use. A 2025 meta-analysis found that current e-cigarette users had 1.48 times higher odds (95% CI: 1.36–1.61) of COPD compared to non-users, potentially due to similar mechanisms of oxidative stress and inflammation from inhaled particulates and flavoring chemicals, though long-term data specific to emphysema remain limited.[41] The post-World War II surge in cigarette consumption, which peaked in the United States during the 1960s with adult prevalence exceeding 40%, precipitated a marked rise in emphysema incidence and mortality through the 1970s and 1980s as the 20- to 30-year latency period for disease manifestation elapsed.[42] This temporal pattern reflected broader global trends, where increased smoking among men and later women amplified the population-level burden of smoking-attributable emphysema.[43] Smoking cessation confers substantial benefits by attenuating the accelerated loss of lung function, as evidenced by reduced rates of forced expiratory volume in one second (FEV1) decline post-quitting. In the Lung Health Study, sustained quitters experienced an annual FEV1 decline of approximately 50 mL/year, compared to 80 mL/year among continuing smokers, highlighting how cessation halts further inflammatory progression and preserves residual lung capacity.[44]

Genetic Factors

Alpha-1 antitrypsin deficiency (A1ATD) represents the most well-established genetic risk factor for emphysema, arising from mutations in the SERPINA1 gene on chromosome 14, which encodes the alpha-1 antitrypsin (AAT) protein, a key serine protease inhibitor.[45] This condition follows an autosomal codominant inheritance pattern, where the severity of deficiency depends on the combination of alleles inherited from each parent.[46] The PI*ZZ genotype, resulting from two deficient Z alleles, leads to profound AAT deficiency (typically less than 15% of normal levels) and predisposes individuals to early-onset panlobular emphysema, often manifesting in the third or fourth decade of life, particularly in the lower lobes of the lungs.[47] A1ATD accounts for approximately 1-3% of severe chronic obstructive pulmonary disease (COPD) cases, including emphysema, in populations of European descent.[48] The PIZ allele frequency is estimated at 1-2% among individuals of European ancestry, though the homozygous PIZZ genotype is rarer, affecting about 1 in 2,500 to 5,000 such individuals.[47] In the pathogenesis of emphysema associated with A1ATD, reduced circulating AAT levels fail to adequately inhibit neutrophil elastase released during inflammation, resulting in unopposed proteolytic activity that progressively destroys alveolar walls and lung parenchyma.[49] This protease-antiprotease imbalance is exacerbated in A1ATD, contributing to the characteristic tissue destruction observed in affected lungs.[50] Beyond SERPINA1, variants in other genes have been implicated in modulating emphysema susceptibility, often through interactions with environmental factors like smoking. Polymorphisms in the matrix metalloproteinase 9 (MMP9) gene, which encodes an enzyme involved in extracellular matrix degradation, have been associated with increased risk of emphysema and COPD progression in certain populations.[51] Similarly, single nucleotide polymorphisms in the tumor necrosis factor (TNF) gene, particularly those promoting elevated inflammatory cytokine production, may heighten susceptibility to lung tissue damage in emphysema.[52] Research into polygenic risk scores, which aggregate the effects of multiple genetic variants across the genome, is emerging as a tool to predict emphysema and COPD liability, identifying individuals at higher risk even in the absence of severe monogenic deficiencies like A1ATD.[53] Screening for A1ATD is recommended for all patients diagnosed with COPD or emphysema, with particular emphasis on those presenting with early-onset disease (before age 45), nonsmokers, or individuals with a family history of lung disease.[54] Genotyping or phenotyping via blood tests can confirm A1ATD, enabling targeted monitoring and intervention to mitigate progression.[50]

Environmental and Occupational Exposures

Environmental and occupational exposures to airborne irritants represent significant non-tobacco risk factors for emphysema, particularly through chronic inflammation and oxidative stress in the lung parenchyma. Long-term exposure to fine particulate matter (PM2.5) has been associated with increased risk of chronic obstructive pulmonary disease (COPD), including emphysema, by promoting alveolar destruction and reduced lung function, especially in non-smokers. Ozone exposure exacerbates this risk, with studies showing combined effects of ambient ozone and household air pollution contributing to COPD onset in young adults. Biomass fuel smoke from indoor cooking, prevalent in low- and middle-income countries, elevates PM2.5 levels up to 100 times above safe thresholds, leading to a 2.8- to 3-fold higher odds of COPD among exposed women and children in poorly ventilated homes. Secondhand smoke and cooking fumes in low-income settings further compound indoor air pollution risks, accelerating emphysematous changes through persistent irritant inhalation. Occupational hazards, particularly in mining and welding, involve inhalation of inorganic dusts that directly contribute to emphysematous lung damage. Coal dust exposure in mining is linked to coal workers' pneumoconiosis, which often features centrilobular emphysema alongside fibrosis, with odds ratios exceeding 3 for prolonged exposure. Silica dust, common in mining and construction, induces similar destructive changes, while cadmium fumes from welding and battery production activate matrix metalloproteinases and inflammation, independently causing emphysema even in never-smokers. These exposures heighten the risk of emphysema with impaired diffusing capacity, with odds ratios up to 3.79 in susceptible individuals. Joint statements from the American Thoracic Society (ATS) and European Respiratory Society (ERS) estimate that occupational exposures account for approximately 14% of COPD cases overall and up to 31% among never-smokers, with higher attributable risks (10-20%) in dusty trades like mining and manufacturing. Professions such as coal miners, welders, and construction workers show prevalence ratios of 1.7 or greater for COPD after 10 years of exposure. These risks often synergize with tobacco smoking, amplifying disease progression. Geographically, industrial regions with heavy mining activity exhibit elevated emphysema prevalence; in Central Appalachia, COPD affects 19.6% of adults aged 40 and older—over three times the U.S. national average—driven by coal and silica dust from thin-seam mining operations.

Other Etiologies

Other etiologies of emphysema are uncommon and collectively account for less than 5% of cases, predominantly affecting non-smokers.[2] Infections contribute to emphysema through mechanisms such as immune dysregulation or scarring. Human immunodeficiency virus (HIV) infection is associated with an increased risk of emphysema independent of smoking, driven by chronic immune activation, inflammation, and protease-antiprotease imbalance in the lungs.[55] Similarly, prior pulmonary tuberculosis can lead to secondary emphysema via extensive scarring and fibrosis that distorts lung architecture and promotes compensatory overinflation in adjacent areas.[56] Autoimmune diseases, particularly connective tissue disorders, can induce paracicatricial emphysema, where alveolar destruction occurs around fibrotic scars. Rheumatoid arthritis is a notable example, often presenting with combined pulmonary fibrosis and emphysema (CPFE), characterized by upper-lobe emphysema and lower-lobe fibrosis due to chronic inflammation and autoantibody-mediated tissue damage.[57] Iatrogenic causes include certain medical interventions and drug abuse practices. Radiation therapy to the thorax may rarely result in bullous or localized emphysematous changes as a late complication of radiation-induced lung injury, though fibrosis is more typical.[58] Intravenous abuse of drugs like methylphenidate (Ritalin), which contains talc as a filler, leads to "Ritalin lung"—a form of panlobular emphysema caused by talc microemboli that incite granulomatous inflammation and progressive alveolar destruction.[59] Relatedly, intravenous talc from other crushed medications can produce similar talc granulomatosis and secondary emphysema through vascular occlusion and foreign body reactions.[59] Congenital anomalies represent another rare etiology, with congenital lobar emphysema arising from intrinsic bronchial cartilage deficiencies or extrinsic bronchial compression, leading to air trapping and hyperinflation of affected lobes during early development.[60]

Clinical Presentation

Respiratory Symptoms

The primary respiratory symptom of emphysema is dyspnea, or shortness of breath, which typically begins insidiously during physical exertion and progresses over years to occur even at rest as lung damage advances.[1] This symptom arises from airflow obstruction due to alveolar destruction and air trapping, increasing the work of breathing and limiting daily activities.[2] Dyspnea severity is often assessed using the modified Medical Research Council (mMRC) scale, a five-point tool ranging from 0 (no breathlessness except with strenuous exercise) to 4 (too breathless to leave the house or breathless when dressing), which helps correlate symptoms with disease impact.[61] In pure emphysema, cough is usually minimal and dry, with little sputum production, distinguishing it from chronic bronchitis where productive cough predominates; however, some patients may experience occasional coughing as the disease overlaps with other COPD components.[1][2] Wheezing, a high-pitched whistling sound during exhalation, and chest tightness often accompany these symptoms, resulting from hyperinflation and trapped air in the damaged alveoli, which narrows airways and causes a sensation of pressure.[4][1] Acute exacerbations represent sudden worsenings of these respiratory symptoms, frequently triggered by respiratory infections such as viral or bacterial pathogens, leading to intensified dyspnea, increased cough, and greater respiratory effort that may require medical intervention.[62][63] The overall symptom timeline in emphysema follows a gradual progression aligned with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages, where early stages (GOLD 1-2) feature mild exertional dyspnea and minimal cough, advancing in later stages (GOLD 3-4) to severe, persistent symptoms at rest with frequent exacerbations, reflecting worsening airflow limitation.[64][2]

Systemic Manifestations

Emphysema, as a primary component of chronic obstructive pulmonary disease (COPD), extends its pathological effects beyond the pulmonary system, leading to significant multi-organ involvement. Systemic manifestations arise from chronic hypoxemia, persistent inflammation, and the resulting physiological adaptations, contributing to increased morbidity and reduced quality of life.[30] One prominent cardiovascular complication is cor pulmonale, characterized by right ventricular hypertrophy and dilation secondary to pulmonary hypertension induced by alveolar destruction and vascular remodeling in emphysema. This right heart strain impairs cardiac output and exacerbates hypoxemia, occurring in up to 30-50% of advanced cases and serving as a marker of disease severity.[65][66] In emphysema patients, cor pulmonale is often subtle ("cor pulmonale parvus") but correlates with reduced exercise tolerance and higher mortality risk.[67] Cachexia manifests as involuntary weight loss, skeletal muscle wasting, and fat depletion, driven by systemic inflammation involving elevated cytokines such as tumor necrosis factor-alpha and interleukin-6. This condition affects 20-40% of emphysema patients, particularly those with severe airflow obstruction, and is linked to accelerated protein catabolism and impaired nutrient utilization.[68][69] Muscle wasting further diminishes peripheral strength and endurance, compounding respiratory disability.[70] Osteoporosis, marked by reduced bone mineral density and increased fracture risk, is prevalent in 20-40% of advanced emphysema cases due to factors including chronic hypoxia, corticosteroid therapy, and physical immobility from dyspnea. Hypoxia disrupts osteoblast function and promotes osteoclast activity, while long-term glucocorticoids inhibit bone formation.[71][72] Vertebral fractures, in particular, can worsen posture and respiratory mechanics, creating a vicious cycle.[73] Chronic fatigue and depression are common neuropsychiatric effects, stemming from persistent hypoxemia and diminished physical activity levels. Fatigue, reported by over 70% of patients, arises from reduced oxygen delivery to muscles and central nervous system fatigue, severely limiting daily functioning.[74][75] Depression affects approximately 40% of individuals with emphysema, exacerbated by hypoxemia-induced neurochemical imbalances and social isolation from activity restriction, and is associated with poorer adherence to therapy.[76][77] Emphysema also heightens the risk of comorbidities such as cardiovascular disease (CVD) and type 2 diabetes, with patients facing 2-3 times the incidence compared to age-matched controls. Systemic inflammation and oxidative stress in emphysema promote atherosclerosis and endothelial dysfunction, elevating CVD events like myocardial infarction.[78][79] Similarly, insulin resistance is amplified by chronic inflammation and adipokine dysregulation, increasing diabetes prevalence by 1.5-2 fold.[80][81] These comorbidities synergistically worsen prognosis, underscoring the need for integrated management.[82]

Diagnosis

Clinical Assessment

The clinical assessment of emphysema begins with a detailed history-taking to identify risk factors and symptom progression. Clinicians inquire about smoking history, as 80-90% of cases are associated with tobacco use, typically manifesting after at least 20 pack-years of exposure.[2] Occupational and environmental exposures, such as dust, chemicals, or biomass fuels, are also explored, particularly in non-smokers or those from developing regions.[2] A family history of alpha-1 antitrypsin deficiency (A1ATD) is critical, affecting 1-2% of patients and often leading to earlier disease onset.[2] The history further documents symptom onset, including chronic dyspnea and cough that initially occur with exertion but progress to rest, guiding the evaluation of disease severity.[2] Physical examination reveals signs of hyperinflation and airflow limitation in advanced emphysema. Inspection may show a barrel chest due to increased anterior-posterior diameter from lung hyperinflation.[2] Auscultation often detects prolonged expiratory phase and decreased breath sounds bilaterally, reflecting airway obstruction and reduced air movement.[2] In severe cases, use of accessory respiratory muscles, such as the sternocleidomastoid, indicates increased work of breathing.[2] Severity grading incorporates the BODE index, a multidimensional tool that predicts mortality and prognosis more effectively than FEV1 alone in emphysema and chronic obstructive pulmonary disease (COPD). It assesses four components: body mass index (B), degree of airflow obstruction via FEV1 (O), dyspnea using the modified Medical Research Council scale (D), and exercise capacity measured by the 6-minute walk distance (E). Higher scores indicate greater severity and poorer outcomes. Red flags during assessment prompt further investigation to rule out alternative or complicating conditions. Early onset of symptoms, particularly before age 45 in non-smokers, suggests genetic causes like A1ATD.[2] Hemoptysis, though uncommon in uncomplicated emphysema, indicates potential alternative diagnoses such as infection, bronchiectasis, or malignancy, necessitating urgent referral.[2] Patient-reported outcomes enhance the assessment by capturing health-related quality of life impacts. The St. George's Respiratory Questionnaire (SGRQ) is a validated tool for emphysema and COPD, measuring symptoms, activity limitations, and psychosocial effects through three domains, with total scores ranging from 0 to 100 (higher indicating worse quality of life). Respiratory symptoms like dyspnea and cough, as reported by patients, inform the interpretation of these scores during clinical evaluation.[2]

Imaging Techniques

Chest X-ray remains the initial imaging modality for evaluating suspected emphysema, commonly revealing hyperinflation with flattened diaphragms, increased retrosternal airspace, and barrel-shaped chest configuration, along with potential bullae or increased lucency.[83] However, its sensitivity is limited, particularly for mild or early disease, with reported detection rates as low as 40% when compared to computed tomography (CT) findings.[84] Computed tomography (CT), especially high-resolution CT (HRCT), is the gold standard for confirming emphysema diagnosis and assessing its extent, as it directly visualizes parenchymal destruction through low-attenuation areas (typically defined by Hounsfield units below -950 HU) that correspond to alveolar wall loss.[84] However, emphysematous changes visible on CT indicate structural emphysema but do not always mean COPD, as COPD diagnosis requires spirometric evidence of persistent airflow limitation (e.g., post-bronchodilator FEV1/FVC below the lower limit of normal or <0.7 per GOLD criteria). Emphysematous changes can occur without airflow obstruction in some smokers, obese patients, or other conditions, and such cases may be referred to as pre-COPD.[85][7] HRCT enhances diagnostic utility by providing detailed cross-sectional images that distinguish emphysema patterns, such as centrilobular involvement predominantly in upper lobes versus panlobular distribution in lower lobes.[84] Quantitative assessment on CT, including the Goddard score—a semi-quantitative visual method scoring emphysema involvement (0-4) across six lung zones for a total of 0-24—correlates strongly with automated densitometric measures and aids in evaluating disease severity and heterogeneity. Emerging imaging modalities like magnetic resonance imaging (MRI) offer complementary functional insights without ionizing radiation; for instance, oxygen-enhanced MRI and dynamic contrast-enhanced perfusion MRI detect ventilation-perfusion (V/Q) mismatches in emphysematous regions, supporting evaluation of gas exchange abnormalities.[84] Quantitative CT techniques further enable longitudinal tracking of emphysema progression by measuring changes in low-attenuation volume over time, which is valuable for monitoring therapeutic responses.[84] Radiation exposure from CT scans poses considerations for repeated imaging in emphysema patients, but low-dose protocols (e.g., 20-30 mAs) maintain diagnostic accuracy for emphysema quantification while reducing effective dose to levels comparable to chest X-rays, minimizing long-term risks.[86]

Pulmonary Function Testing

Pulmonary function testing (PFT) is essential for confirming the diagnosis of emphysema, assessing its severity, and monitoring disease progression by quantifying airflow limitation, hyperinflation, and gas exchange impairment. These tests reveal characteristic patterns of obstruction and alveolar destruction, distinguishing emphysema from other respiratory conditions. In emphysema, PFTs typically demonstrate irreversible airflow obstruction, air trapping, and reduced diffusing capacity, with results interpreted against predicted values based on age, sex, height, and ethnicity.[87] Spirometry is the cornerstone of PFT in emphysema, measuring forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1), with the FEV1/FVC ratio serving as the primary diagnostic criterion. A post-bronchodilator FEV1/FVC ratio below 0.70 indicates persistent airflow obstruction consistent with chronic obstructive pulmonary disease (COPD), of which emphysema is a major pathological component. The diagnosis of COPD requires confirmation of this persistent airflow limitation via spirometry. Emphysematous changes on computed tomography (CT) do not always indicate COPD, as such changes can occur without airflow obstruction (e.g., in some smokers, obese patients, or other conditions), and individuals with these imaging findings but normal spirometry do not meet COPD diagnostic criteria and may be considered "Pre-COPD" or require management for symptoms or risk factors. FEV1 is often reduced, with severity graded as mild (≥80% predicted), moderate (50% to <80% predicted), severe (30% to <50% predicted), or very severe (<30% predicted). Post-bronchodilator testing is crucial to exclude reversible components like asthma, as emphysema shows limited reversibility.[88][87][89] Lung volume measurements, obtained via body plethysmography or gas dilution techniques, detect hyperinflation and air trapping hallmarks of emphysema. Total lung capacity (TLC) is frequently increased (>120% predicted) due to loss of elastic recoil, while residual volume (RV) rises markedly from premature airway closure. The RV/TLC ratio, normally <35%, exceeds this threshold (often >60% in severe cases) and signifies air trapping, correlating with dyspnea and exercise intolerance. These abnormalities reflect emphysematous destruction of alveolar walls, leading to dynamic hyperinflation during expiration.[87][90][91] Diffusing capacity for carbon monoxide (DLCO) quantifies gas exchange efficiency and is markedly reduced in emphysema due to alveolar-capillary membrane destruction and loss of vascular bed. DLCO values below 75% predicted, even with normal spirometry, support an emphysema diagnosis, as it isolates parenchymal damage from pure airway obstruction. This is particularly relevant in cases where emphysema is present without the airflow obstruction required for a COPD diagnosis. This test is particularly useful in early or mild cases where spirometry may be less sensitive.[87] Arterial blood gas (ABG) analysis complements PFT by directly measuring partial pressure of oxygen (PaO2) and carbon dioxide (PaCO2) to evaluate gas exchange abnormalities, particularly hypoxemia (PaO2 <55 mmHg) or hypercapnia in advanced emphysema, guiding decisions for oxygen therapy. In patients with mild emphysema (a form of mild COPD), resting oxygen saturation (SpO2) is typically normal, ranging from 95% to 100%, similar to healthy individuals. Hypoxemia at rest is uncommon in mild cases, and supplemental oxygen is not routinely required unless desaturation occurs during exertion or in more advanced disease. Targets of 88-92% apply mainly to moderate-severe COPD with chronic hypoxemia or hypercapnia risk, not mild emphysema.[2][89] Exercise testing, such as the 6-minute walk test (6MWT), evaluates functional capacity and oxygen desaturation in emphysema patients. During the 6MWT, a drop in oxygen saturation (SpO2) of ≥4%—often to ≤88%—may occur even in milder cases but is more common and pronounced in moderate to severe disease, reflecting ventilation-perfusion mismatch and hypoxemia under stress. This desaturation occurs rapidly (within the first minute) and predicts mortality risk, guiding oxygen therapy decisions.[92][93] Serial PFTs enable monitoring of emphysema progression, with annual FEV1 decline averaging 50-100 mL/year in moderate to severe cases, accelerated by ongoing smoking or exacerbations. This rate varies by phenotype, with emphysematous COPD showing steeper declines (e.g., 13 mL/year greater than non-emphysematous forms), emphasizing the need for annual spirometry to track response to interventions like smoking cessation or pharmacotherapy.[94][95][96]

Differential Diagnosis

Emphysema, a form of chronic obstructive pulmonary disease (COPD), often presents with progressive dyspnea and airflow limitation, necessitating careful differentiation from other respiratory and cardiac conditions to guide appropriate management.[2] Symptoms such as exertional shortness of breath can overlap with various disorders, but distinct clinical features, pulmonary function tests (PFTs), imaging, and therapeutic responses aid in distinguishing emphysema.[97] Asthma is a primary differential, characterized by reversible airflow obstruction in response to bronchodilators or allergens, unlike the largely irreversible limitation seen in emphysema.[2] Patients with asthma often have a history of atopy, episodic wheezing triggered by irritants or exercise, nocturnal symptoms, and elevated eosinophil counts or IgE levels, which are less common in emphysema.[97] PFTs in asthma typically show significant improvement in forced expiratory volume in one second (FEV1) post-bronchodilator, whereas emphysema demonstrates minimal reversibility.[2] Chronic bronchitis, another COPD phenotype, must be differentiated based on predominant productive cough with sputum hypersecretion for at least three months in two consecutive years, often preceding airflow obstruction, in contrast to the dyspnea-dominant presentation of emphysema with less sputum production.[97] While both share smoking history as a risk factor, chronic bronchitis features less hyperinflation on imaging and may show normal spirometry in early stages, whereas emphysema exhibits marked air trapping and reduced diffusing capacity.[2][97] Interstitial lung disease (ILD) presents with restrictive physiology and fibrosis on high-resolution computed tomography (HRCT), differing from the obstructive pattern and bullous lucencies characteristic of emphysema.[2] Dyspnea in ILD is often accompanied by dry cough and fine inspiratory crackles, with PFTs revealing reduced total lung capacity and no significant bronchodilator response, unlike the hyperinflation and airflow limitation in emphysema.[2] Heart failure mimics emphysema through exertional dyspnea and fatigue, but features orthopnea, paroxysmal nocturnal dyspnea, peripheral edema, and signs of fluid overload, which are absent in isolated emphysema.[98] Echocardiography is key to identifying cardiac dysfunction such as reduced ejection fraction or elevated pulmonary pressures in heart failure, while emphysema lacks these findings and shows hyperinflation on chest imaging.[98][2] In cases of early-onset emphysema, particularly in nonsmokers or those under 45 years, alpha-1 antitrypsin (AAT) deficiency should be excluded through serum AAT level measurement and genetic testing, as it causes a genetic form of panlobular emphysema distinct from smoking-related centrilobular disease.[2] Low AAT levels confirm the deficiency, which predisposes to basilar-predominant emphysema and may require augmentation therapy, unlike typical emphysema management.[46] Key discriminators include PFT patterns—obstructive with low FEV1/forced vital capacity ratio and reduced diffusing capacity in emphysema versus restrictive or reversible changes in alternatives—HRCT findings of emphysema-specific lucencies and air trapping versus fibrosis or consolidation elsewhere, and poor response to bronchodilators or lack of improvement with diuretics in emphysema compared to asthma or heart failure.[2][97][98]

Classification and Types

Centrilobular Emphysema

Centrilobular emphysema, also known as proximal acinar emphysema, is the most common subtype of pulmonary emphysema, characterized by the abnormal permanent enlargement of airspaces in the central portion of the secondary pulmonary lobule, accompanied by destruction of their walls without obvious fibrosis.[2] It predominantly affects the proximal respiratory bronchioles within the acinus, with a characteristic upper lobe predominance, particularly in the superior segments of the lower lobes and the inner zones of the lung.[99] This form accounts for the majority of emphysema cases related to cigarette smoking, with autopsy studies indicating its presence in up to 50% of adult smokers, and it represents the predominant pattern in 70-90% of smoking-associated chronic obstructive pulmonary disease (COPD) cases.[99][2] The pathogenesis of centrilobular emphysema is closely linked to long-term cigarette smoking, which induces chronic inflammation in the proximal acinus by recruiting inflammatory cells such as macrophages, neutrophils, and T lymphocytes.[100] These cells release proteolytic enzymes, including neutrophil elastase and matrix metalloproteinases, which degrade elastin and other extracellular matrix components in the respiratory bronchioles, leading to airspace enlargement and loss of elastic recoil.[2] Smoking also promotes oxidative stress and mucus hypersecretion, exacerbating the protease-antiprotease imbalance and focal destruction that begins centrally and spares the distal alveoli and alveolar ducts initially.[27] In advanced stages, the destruction can progress to involve more of the acinus, potentially resembling panlobular patterns with confluent emphysematous spaces.[99] On high-resolution computed tomography (HRCT), centrilobular emphysema appears as small, round, centrilobular lucencies (typically 1-10 mm) with ill-defined borders in early stages, centered around the centrilobular arteries and evenly distributed without extensive lung hyperinflation.[27] These lucencies reflect the focal destruction, initially sparing the distal alveolar regions, which helps distinguish it from other subtypes.[99] Clinically, the upper lobe predominance of centrilobular emphysema correlates with relatively preserved gas exchange in early disease due to the heterogeneous distribution and maintenance of some alveolar-capillary units in affected areas, resulting in less severe hypoxemia compared to more uniform destructive patterns.[100] However, as the disease advances, airflow limitation worsens due to reduced elastic recoil and airway collapse during expiration.[2]

Panlobular Emphysema

Panlobular emphysema, also known as panacinar emphysema, is a subtype of pulmonary emphysema defined by the uniform enlargement and destruction of airspaces throughout the entire acinus, extending from the respiratory bronchioles to the alveoli within the secondary pulmonary lobule.[27] This results in a diffuse, homogeneous pattern of tissue loss without the proximal-distal gradient seen in other forms.[84] Unlike centrilobular emphysema, which predominantly affects the upper lobes in smokers, panlobular emphysema shows a basal predominance, with more severe changes typically observed in the lower lung fields.[27][84] The condition is strongly associated with alpha-1 antitrypsin deficiency (A1ATD), a genetic disorder that impairs the protective function of alpha-1 antitrypsin against proteolytic enzymes, leading to unchecked lung tissue degradation.[84] It is also linked to Swyer-James syndrome, a post-infectious bronchiolitis obliterans that can cause unilateral hyperlucency and lobular involvement.[27] In pathogenesis, panlobular emphysema arises from widespread protease-antiprotease imbalance, often due to excess elastase activity from inflammatory cells, resulting in even alveolar wall breakdown across the lobule without regional variation.[27][84] On imaging, high-resolution computed tomography (HRCT) reveals diffuse low-attenuation regions encompassing the entire lobule, appearing more homogeneous and ill-defined compared to the patchy, centrilobular distribution.[27][101] These changes may show polygonal borders in localized forms or blend into broader hazy opacities in diffuse cases, with reduced visibility of peripheral vessels as severity increases.[101] Clinically, panlobular emphysema often manifests with an earlier onset and faster disease progression, particularly in non-smokers affected by hereditary factors such as A1ATD.[84] Patients may experience greater dyspnea and reduced exercise capacity—such as a 6-minute walk distance at 73% of predicted value—independent of the degree of airflow obstruction, alongside hyperinflation and diminished diffusing capacity.[101]

Paraseptal Emphysema

Paraseptal emphysema, also known as distal acinar emphysema, is defined by the enlargement of airspaces in the distal portion of the acinus, specifically adjacent to the pleura and interlobular septa.[102] This subtype predominantly affects the peripheral regions of the lung lobule, involving the alveolar ducts and sacs near the lung surface.[2] Unlike more central forms, it is confined to the margins of the secondary pulmonary lobule, sparing the central proximal acinar structures.[101] The pathogenesis of paraseptal emphysema involves localized destruction of alveolar walls in the distal acinus, often linked to inflammatory processes from cigarette smoke exposure that target the peripheral airways and adjacent vasculature.[2] This destruction leads to airspace enlargement without significant involvement of bronchioles, potentially contributing to disruptions in pulmonary or pleural capillaries.[102] While the exact mechanisms remain under study, the pattern suggests a gradient of injury from the pleura inward, distinguishing it from other emphysematous subtypes.[27] Prevalence of paraseptal emphysema varies by population, occurring in approximately 3% of community-dwelling individuals but rising to 15% among smokers with chronic obstructive pulmonary disease (COPD), with a higher incidence in men.[102] It is commonly identified in current or former smokers, though it frequently remains asymptomatic and is discovered incidentally on imaging.[101] This subtype often coexists with other forms of emphysema but can present independently.[2] On imaging, paraseptal emphysema manifests as subpleural regions of low attenuation or well-defined cystic spaces on high-resolution computed tomography (HRCT), typically along the fissures and peripheral lung zones.[27] These lucencies are most prominent in the upper lobes and dorsal surfaces, aiding differentiation from centrilobular patterns.[101] The presence of extensive paraseptal changes increases the risk of secondary pneumothorax due to potential rupture of weakened peripheral structures.[102] Clinically, paraseptal emphysema is usually associated with minimal or no respiratory symptoms, particularly when mild and isolated, allowing affected individuals to remain unaware of its presence.[2] Symptoms may only emerge if complications arise, such as rupture leading to pneumothorax, which can occur spontaneously in younger adults despite limited overall lung function impairment.[27] Routine monitoring is recommended for those with identified changes to assess progression.[101]

Bullous Emphysema

Bullous emphysema represents a distinct subtype of emphysema characterized by the formation of bullae, defined as sharply demarcated, air-filled spaces greater than 1 cm in diameter within the lung parenchyma, resulting from the irreversible destruction and enlargement of alveolar spaces. These bullae typically arise from paraseptal emphysema, where damage is concentrated in the peripheral acini near the pleura. Approximately 80% of patients with bullae also exhibit underlying emphysema, often linked to chronic obstructive pulmonary disease (COPD).[103] The pathogenesis involves the coalescence of adjacent alveoli destroyed by chronic inflammation, commonly triggered by cigarette smoke or other irritants, leading to the loss of alveolar walls and elastic recoil. This process forms thin-walled cystic structures that impair gas exchange and contribute to airflow limitation. Bullae predominantly develop in the apical regions of the upper lobes, where paraseptal changes are most pronounced, though they can occur subpleurally or more diffusely in advanced cases.[103][100][104] On imaging, bullous emphysema manifests as large, lucent areas on computed tomography (CT) scans, often compressing and displacing adjacent normal lung tissue, which helps differentiate it from other cystic lesions. Chest radiographs may show radiolucent bullae outlined by thin white lines, but CT provides superior sensitivity for detection and characterization. Clinically, patients experience progressive dyspnea, primarily due to the mechanical compression of functional lung parenchyma by expanding bullae; a significant complication is the risk of bulla rupture, which can lead to spontaneous pneumothorax.[103][27]

Paracicatricial Emphysema

Paracicatricial emphysema, also known as irregular or scar emphysema, is a subtype of emphysema characterized by localized destruction of alveolar walls adjacent to areas of pulmonary fibrosis or scarring. This form is distinct from other emphysema types due to its direct association with fibrotic processes, resulting in airspace enlargement limited to the vicinity of scars.[105] It commonly occurs around fibrotic scars caused by prior infections such as tuberculosis, radiation therapy, or granulomatous diseases like sarcoidosis. The scarring leads to architectural distortion in the surrounding lung parenchyma, where normal lung tissue is pulled and stretched by the contracting fibrous tissue.[105][106] The pathogenesis involves mechanical traction exerted by the fibrotic scars, which dilates and enlarges adjacent airspaces without the typical proteolytic destruction seen in smoking-related emphysema. This traction-based mechanism causes irregular dilation of alveoli and respiratory bronchioles near the scar, often resulting in mild to moderate airspace enlargement that is not extensive.[106][107] Paracicatricial emphysema is frequently observed in advanced lung diseases involving fibrosis, including cases with overlap between chronic obstructive pulmonary disease (COPD) and interstitial lung abnormalities, though specific prevalence data are limited. It is noted in a subset of patients with mixed obstructive and restrictive lung involvement.[108][109] On imaging, high-resolution computed tomography (HRCT) reveals characteristic irregular lucencies or focal areas of low attenuation adjacent to fibrotic bands, scars, or areas of architectural distortion, often appearing as enlarged airspaces or small bullae abutting the scarred regions. These findings help differentiate it from more diffuse emphysema patterns.[110][111] Clinically, paracicatricial emphysema is often asymptomatic unless extensive, with symptoms primarily attributable to the underlying fibrotic condition. It contributes to a mixed pattern on pulmonary function tests, combining obstructive defects from airspace destruction with restrictive impairment due to fibrosis, such as reduced forced vital capacity alongside airflow limitation.[112]

Alpha-1 Antitrypsin Deficiency-Related Emphysema

Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder that predisposes individuals to early-onset emphysema, particularly in those with severe deficiency such as the PI*ZZ genotype. This form of emphysema is characterized by a distinct pathology where reduced levels of the protective protease inhibitor alpha-1 antitrypsin lead to unchecked elastase activity in the lungs, resulting in tissue destruction. Unlike smoking-related emphysema, which often affects upper lobes, AATD-related emphysema exhibits a unique distribution and progression pattern influenced by the underlying genetic defect.[113] The emphysema phenotype in AATD is predominantly panlobular with a basal predominance, involving uniform destruction across the acinus and primarily affecting the lower lobes of the lungs. This distribution arises from the gravitational settling of pollutants and the relatively lower AAT concentrations in the lower lung zones, exacerbating proteolytic damage. High-resolution computed tomography typically reveals diffuse panlobular emphysema in the lung bases, often progressing to severe airflow obstruction by middle age. Screening for AATD is recommended in patients with early-onset emphysema, especially those with lower lobe involvement, to identify this treatable genetic cause.[114][115] Onset of emphysema in AATD typically occurs earlier in smokers, around age 30-40 years, compared to non-smokers, where symptoms may emerge between 45-50 years. Smoking accelerates lung function decline by further impairing AAT function and increasing oxidative stress, leading to dyspnea and reduced exercise tolerance at a younger age. In non-smokers, environmental factors like secondhand smoke exposure in childhood can also hasten symptom onset, though the progression is generally slower.[116][117] Liver involvement complicates approximately 10-15% of AATD cases in adults, where misfolded AAT proteins polymerize and accumulate in hepatocytes, leading to cirrhosis. These polymers trigger endoplasmic reticulum stress and inflammation, distinct from the lung pathology, and may manifest as elevated liver enzymes or portal hypertension even without prior childhood liver disease. The PI*ZZ genotype confers the highest risk for this gain-of-function liver toxicity.[47] Diagnosis of AATD-related emphysema involves measuring serum AAT levels, with concentrations below 80 mg/dL indicating potential deficiency and prompting further evaluation. Confirmatory genotyping identifies the PI*ZZ variant as the most severe form, associated with AAT levels of 20-35 mg/dL, while phenotyping distinguishes deficient alleles like Z and S. Early diagnosis through targeted screening in at-risk populations, such as those with unexplained early emphysema, enables monitoring for both pulmonary and hepatic complications.[113][118] Without intervention, prognosis in AATD-related emphysema features accelerated lung function decline, with forced expiratory volume in one second (FEV1) decreasing at 80-100 mL per year in smokers, compared to slower rates in non-smokers. This rapid progression correlates with baseline FEV1 levels and smoking history, increasing risks of respiratory failure and mortality by age 50-60 in severe cases. Longitudinal studies highlight the variability, but overall survival is reduced without addressing modifiable factors like tobacco exposure.[119][120]

HIV-Associated Emphysema

HIV-associated emphysema refers to the accelerated development of emphysema in individuals living with HIV, characterized by a higher prevalence and more severe manifestations compared to HIV-uninfected populations. Studies have reported emphysema prevalence rates of 15-33% among people with HIV (PWH), particularly those who smoke, compared to 2-15% in matched controls without HIV.[121][122] This condition predominantly manifests as centrilobular emphysema, often linked to smoking history, though HIV infection independently elevates risk even in non-smokers, with rates up to 18% in lifelong non-smoking PWH versus 4% in controls.[123][124] The pathogenesis involves HIV-induced immune dysregulation, particularly profound depletion of CD4+ T-cells in the lungs, which leads to unchecked chronic inflammation and protease-antiprotease imbalance. This depletion, driven by activation-induced cell death, impairs the lung's ability to regulate inflammatory responses to insults like cigarette smoke, resulting in alveolar destruction.[125][126] Even with antiretroviral therapy (ART), persistent low CD4/CD8 ratios correlate with increased emphysema risk, highlighting ongoing immune impairment despite viral suppression.[127] Emphysema in PWH often presents earlier and more severely than in the general population, with accelerated progression independent of smoking in some cases and synergistic worsening in smokers.[126][128] On computed tomography (CT) imaging, it shows diffuse involvement across lung zones, with a higher propensity for bullae formation and greater overall emphysema severity compared to HIV-uninfected individuals.[124][129] Clinically, PWH with emphysema exhibit worse diffusing capacity for carbon monoxide (DLCO) and reduced exercise tolerance, contributing to increased respiratory symptoms and mortality risk.[130][131]

Ritalin Lung

Ritalin lung refers to a rare form of iatrogenic panlobular emphysema resulting from the intravenous injection of crushed methylphenidate (Ritalin) tablets, a practice historically associated with substance abuse. This condition arises when insoluble excipients, particularly talc (magnesium silicate), present in the tablets are emulsified and injected, leading to pulmonary complications. Unlike smoking-related emphysema, it occurs in young individuals without significant tobacco exposure, often presenting as severe, precocious obstructive lung disease.[132] The mechanism involves talc emboli lodging in the pulmonary arterioles and capillaries, provoking a foreign body giant cell reaction that forms granulomas. These granulomas cause vascular occlusion, ischemic necrosis of surrounding tissue, and progressive destruction of alveolar walls, culminating in panlobular emphysema. Although the precise pathogenesis remains incompletely understood, the absence of alpha-1 antitrypsin deficiency in affected patients underscores the role of these particulates rather than genetic factors. This process differs from other talc-related lung diseases, where larger particles may produce more prominent nodular changes.[132][133] The emphysema in Ritalin lung is typically panlobular or focal and predominantly affects the lower lung zones (basal-predominant distribution), though bilateral involvement is common. It was most prevalent among intravenous drug users in the 1970s and 1980s, when methylphenidate diversion for abuse peaked, but cases remain rare today due to changes in formulation and awareness. Small autopsy and clinical series document only a handful of patients, highlighting its uncommon nature even within abuse cohorts.[132][134] On imaging, computed tomography (CT) reveals a micronodular pattern in early stages due to talc granulomas, which may evolve into diffuse emphysematous lucencies with vascular pruning and loss of lung parenchyma. Radiographic findings mimic those of alpha-1 antitrypsin deficiency emphysema but occur in a younger demographic. Clinically, patients—often young non-smokers—experience progressive dyspnea, severe airflow obstruction, and reduced exercise tolerance, with the damage frequently irreversible and leading to respiratory failure in advanced cases.[132][133]

Combined Pulmonary Fibrosis and Emphysema (CPFE)

Combined pulmonary fibrosis and emphysema (CPFE) is a distinct syndrome defined by the coexistence of emphysema predominantly in the upper lung zones and pulmonary fibrosis in the lower lung zones, typically identified on high-resolution computed tomography (HRCT) scans. This entity is characterized by subnormal spirometry with relatively preserved lung volumes, severe impairment in gas exchange as evidenced by reduced diffusing capacity of the lung for carbon monoxide (DLCO), a high prevalence of pulmonary hypertension, and an overall poor prognosis. It most commonly affects older male smokers, distinguishing it from isolated emphysema or idiopathic pulmonary fibrosis (IPF).[135][136][137] The pathogenesis of CPFE involves shared risk factors and mechanisms, with cigarette smoking serving as the primary common trigger in the vast majority of cases. Smoking likely promotes both emphysematous destruction through protease-antiprotease imbalance and fibrotic remodeling via oxidative stress and inflammation. Emerging evidence points to potential genetic links, including telomere dysfunction (e.g., mutations in TERT) and polymorphisms in the MUC5B promoter gene, which may predispose individuals to concurrent airspace enlargement and interstitial scarring. Autoimmune phenomena and gastroesophageal reflux have also been implicated as contributing factors in subsets of patients.[136][137][138] Prevalence estimates for CPFE vary by population and diagnostic criteria, ranging from 1-5% in chronic obstructive pulmonary disease (COPD) cohorts to 8-61% among patients with IPF. It is more frequent in males over 60 years of age, with studies reporting up to 85% of cases occurring in current or former smokers. The syndrome accounts for approximately 5-10% of idiopathic diffuse parenchymal lung diseases in epidemiological records.[136][135][138] On HRCT imaging, CPFE typically manifests as centrilobular or paraseptal emphysema in the upper lobes, often with bullae, alongside basal predominant fibrosis featuring honeycombing (in about 95% of cases), reticular opacities (87%), and traction bronchiectasis (69%). This biphasic distribution contrasts with the more uniform patterns seen in pure emphysema or fibrosis.[135][137][138] Clinically, patients with CPFE present with progressive exertional dyspnea, chronic cough, and bilateral basal crackles, alongside finger clubbing in about 43% of cases. Despite near-normal spirometry, DLCO is markedly reduced (often <40% predicted), reflecting combined ventilatory and diffusive defects. Severe pulmonary hypertension develops in 47-90% of patients at diagnosis, contributing to right heart strain and exercise intolerance. Prognosis is dismal, with median survival of 3-6 years and 5-year survival rates of 35-55%; the presence of pulmonary hypertension halves 5-year survival to around 25%.[135][136][137]

Swyer-James Syndrome

Swyer-James syndrome, also known as Macleod syndrome, is a rare variant of emphysema characterized by unilateral pulmonary hyperlucency resulting from post-infectious lung damage during childhood.[139] This condition involves acquired hypoplasia of one lung or a lobe, leading to reduced vascularity and alveolar hyperdistention, distinguishing it as a post-infectious form of obstructive lung disease rather than the typical smoking-related emphysema.[139] First described in case reports in the early 1950s, it represents a sequela of bronchiolitis obliterans that impairs normal lung growth and function. The etiology of Swyer-James syndrome traces back to severe respiratory infections in infancy or early childhood, most commonly viral bronchiolitis obliterans caused by agents such as adenovirus, respiratory syncytial virus (RSV), measles, or influenza.[139] These infections trigger obliterative bronchiolitis, which damages the small airways and pulmonary vasculature, resulting in arrested alveolar development and hypoplasia of the affected lung.[139] The inflammatory process leads to fibrosis and reduced perfusion, creating a hypoplastic lung with compensatory overinflation of the contralateral lung over time.[140] Key radiographic features include unilateral hyperlucency on chest X-ray due to decreased vascular markings and air trapping, alongside a small pulmonary artery and reduced lung volume on the affected side.[139] Mosaic perfusion is evident, reflecting heterogeneous ventilation and perfusion mismatches, often with bronchiectasis or bullae formation in advanced cases.[140] These changes create a characteristic "small lung" appearance, with the affected hemithorax potentially appearing smaller than the opposite side.[139] Swyer-James syndrome is exceedingly rare, with a prevalence estimated at approximately 0.01% based on large-scale chest radiograph surveys, accounting for less than 1% of all emphysema cases.[141] It is often underdiagnosed due to its subtle presentation and overlap with other unilateral lung pathologies.[139] Computed tomography (CT) imaging is the gold standard for diagnosis, revealing reduced vascularity, air trapping on expiratory views, and mosaic attenuation patterns that confirm the obliterative changes.[139] High-resolution CT may also show emphysema-like destruction, peripheral bronchiectasis, and oligemia (reduced blood flow) in the affected lung, aiding differentiation from congenital or neoplastic causes.[140] Clinically, many individuals with Swyer-James syndrome remain asymptomatic into adulthood, with the condition discovered incidentally on imaging.[139] Symptomatic cases may present with exertional dyspnea, recurrent respiratory infections, or cough, particularly if there is bilateral involvement or significant compensatory hyperinflation of the unaffected lung.[139] Pulmonary function tests typically demonstrate obstructive patterns with reduced diffusion capacity on the affected side.[140]

Congenital Lobar Emphysema

Congenital lobar emphysema (CLE) is a rare congenital anomaly of lung development characterized by progressive overdistension and hyperinflation of one or more pulmonary lobes, resulting from air trapping without parenchymal destruction. This condition arises during fetal lung maturation and typically manifests in the neonatal period, leading to potential respiratory compromise due to compression of adjacent lung tissue and mediastinal shift. Unlike acquired forms of emphysema, CLE stems from intrinsic developmental defects rather than environmental or inflammatory insults.[60] The pathogenesis of CLE primarily involves abnormal bronchial cartilage development, such as dysplasia, hypoplasia, or deficiency, which weakens the airway walls and predisposes them to collapse during expiration. This dynamic airway obstruction traps air within the affected lobe, causing progressive hyperinflation that compresses surrounding normal lung parenchyma and can impair ventilation. In some cases, polyalveolar lobes with excessive alveoli may contribute to increased compliance and air retention, though the exact etiology remains idiopathic in most instances.[142][143] The left upper lobe is the most frequently affected site, involved in approximately 43% to 45% of cases, followed by the right middle lobe (around 32%) and right upper lobe (about 21%); multilobar involvement is rare but possible. This distribution reflects the anatomical vulnerabilities in upper and middle lobe bronchi during embryogenesis.[142][60] Clinical presentation often occurs in the first few months of life, with nearly half of cases symptomatic at birth and the remainder developing signs by six months; symptoms include progressive respiratory distress, wheezing, cyanosis, tachypnea, and feeding difficulties due to the hyperinflated lobe's mass effect. Diagnosis is primarily achieved through chest X-ray, which reveals lobar hyperlucency, mediastinal shift, and potential atelectasis of adjacent lobes, while computed tomography (CT) provides confirmatory detail on the extent of hyperinflation and rules out other malformations. Prenatal ultrasound may occasionally detect it as a cystic lesion.[60][142] The incidence of CLE is estimated at 1 in 20,000 to 30,000 live births, representing about 10% to 15% of all congenital lung malformations, with a slight male predominance. It is more common in term infants and has no strong genetic associations identified to date.[144][145] Management focuses on symptomatic relief, with conservative observation sufficient for asymptomatic or mildly affected infants, as many cases resolve spontaneously. However, for moderate to severe respiratory distress, surgical lobectomy of the affected lobe is the definitive treatment, offering excellent outcomes with low morbidity when performed early. Postoperative prognosis is generally favorable, with most children achieving normal lung function.[60][146]

Focal Emphysema

Focal emphysema is characterized by small, localized areas of permanent airspace enlargement distal to the terminal bronchioles, accompanied by destruction of alveolar walls, but without the widespread involvement typical of advanced emphysematous diseases. This form represents mild, patchy emphysematous changes that do not substantially compromise global lung architecture or function. The term was originally introduced to describe a less severe variant of lung destruction with broader but limited distribution compared to diffuse forms.[147] The primary causes of focal emphysema include age-related alterations known as senile emphysema, compensatory expansion following surgical resection such as lobectomy, and initial inflammatory responses to smoking. Senile emphysema results from natural aging processes that lead to subtle acinar modifications and mild airspace dilation without significant wall destruction, often considered a physiological rather than pathological change. Compensatory emphysema develops when viable lung tissue hyperinflates to offset the loss of function in resected or atelectatic regions, as seen post-lobectomy, restoring partial volume through expansion of the remaining parenchyma. Early cigarette smoking can induce focal centrilobular emphysema through localized inflammation and protease-antiprotease imbalance in the central lobular areas, representing an initial stage of smoke-related damage in asymptomatic individuals.[148][149][150][151] These lesions are typically scattered diffusely across the lungs with only mild involvement, lacking confinement to specific lobes or zones. On computed tomography (CT) imaging, focal emphysema manifests as subtle focal lucencies or low-attenuation regions, often measuring up to 1 cm in diameter and surrounded by normal lung parenchyma, commonly identified incidentally during scans for unrelated issues. High-resolution CT is particularly sensitive for detecting these early, non-confluent changes, while conventional chest radiography may overlook them due to their limited extent.[152][101] Clinically, focal emphysema is generally asymptomatic, with no associated respiratory symptoms such as dyspnea, cough, or sputum production, distinguishing it from symptomatic chronic obstructive pulmonary disease. It tends to progress very slowly or remain stable over time, rarely evolving into diffuse disease without additional risk factors, and thus seldom requires specific management beyond monitoring.[153]

Complications

Respiratory Complications

Emphysema predisposes individuals to several lung-specific complications arising from alveolar destruction, airflow limitation, and impaired gas exchange. These include pneumothorax, recurrent infections, acute exacerbations, pulmonary hypertension, and respiratory failure, which can significantly worsen disease progression and quality of life.[2] Pneumothorax occurs when subpleural bullae rupture, allowing air to escape into the pleural space and causing lung collapse. This complication is particularly life-threatening in severe emphysema due to preexisting lung damage, often requiring urgent intervention such as chest tube drainage. Patients with emphysema face an elevated risk of secondary spontaneous pneumothorax compared to those without underlying lung disease.[1][154][155] Recurrent respiratory infections, such as bronchitis and pneumonia, are common due to impaired mucociliary clearance and mucus hypersecretion in damaged airways. These infections exacerbate inflammation and airflow obstruction, increasing susceptibility in patients with emphysema-dominant chronic obstructive pulmonary disease (COPD). Bacterial and viral pathogens colonize the lower airways more readily, leading to frequent episodes that prolong recovery and contribute to lung function decline.[156][2][157] Acute exacerbations manifest as sudden worsening of dyspnea, cough, and sputum production, typically triggered by respiratory infections or environmental pollutants. In moderate emphysema, patients experience an average of 1-2 exacerbations per year, with frequency increasing alongside disease severity. These events accelerate emphysema progression by promoting further airway inflammation and alveolar damage.[158][2][159] Pulmonary hypertension develops from chronic hypoxemia-induced vasoconstriction in pulmonary arteries, elevating vascular resistance and pressure. This hypoxic pulmonary vasoconstriction, a response to low oxygen levels in emphysematous lungs, leads to right ventricular strain and eventual cor pulmonale, characterized by right heart enlargement and failure. In advanced emphysema, this complication correlates with severe hypoxemia (PaO2 <59 mmHg) and worsens prognosis.[160][65][2] Respiratory failure in emphysema initially presents as type 1 (hypoxemic), with inadequate oxygenation due to ventilation-perfusion mismatch and alveolar hypoventilation. As disease advances, it progresses to type 2 (hypercapnic) failure, involving CO2 retention from worsening airflow limitation and respiratory muscle fatigue. This sequence heightens the risk of acute decompensation during exacerbations, often necessitating mechanical ventilation.[161][162][2]

Systemic Complications

Emphysema contributes to systemic complications through chronic hypoxia, systemic inflammation, and shared risk factors with other diseases, affecting multiple organ systems and increasing morbidity. These extrapulmonary effects arise primarily from the disease's impact on oxygen delivery and inflammatory cascades, leading to heightened vulnerability in non-respiratory tissues. Osteoporosis is a prevalent comorbidity in emphysema patients, with a pooled global prevalence of approximately 38% based on bone mineral density assessments across multiple studies.[163] Chronic hypoxia promotes bone resorption by activating hypoxia-inducible factor 1α (HIF-1α), which enhances osteoclast differentiation and impairs bone formation.[163] This results in a 2- to 5-fold higher risk of osteoporosis compared to age-matched healthy individuals, alongside an elevated fracture risk, particularly vertebral fractures, due to reduced bone density and increased fall propensity.[163] Cardiovascular complications are accelerated in emphysema due to systemic inflammation and oxidative stress, which promote endothelial dysfunction and atherosclerotic plaque formation.[164] Patients face approximately a 2-fold increased odds of cardiovascular disease overall, including ischemic heart disease.[79] Specifically, the risk of myocardial infarction is roughly doubled, independent of traditional risk factors like smoking, with exacerbations further heightening thrombotic tendencies.[79] Cachexia and sarcopenia manifest as significant muscle wasting in emphysema, affecting 15% to 40% of patients and driven by cytokine-mediated catabolism.[68] Elevated levels of proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) activate pathways like NF-κB and the ubiquitin-proteasome system, leading to selective type II fiber atrophy and reduced fat-free mass.[165] This muscle loss exacerbates exercise intolerance and contributes to a negative protein turnover balance, often compounded by systemic inflammation referenced in broader pathophysiology discussions. Mental health issues, including anxiety and depression, show a comorbidity prevalence of around 40% in emphysema patients, stemming from the chronic burden of breathlessness and reduced quality of life.[166] Anxiety affects up to 40% and depression up to 25%, with higher rates in severe cases, correlating with increased exacerbation frequency and poorer disease outcomes.[166] Emphysema slightly elevates lung cancer risk beyond smoking alone, primarily through shared etiological factors like chronic inflammation and genetic susceptibilities.[167] The presence of emphysema on CT imaging is associated with a 2- to 4-fold increased odds of lung cancer, particularly in centrilobular phenotypes, highlighting the interplay of destructive lung remodeling and oncogenic processes.[167]

Management and Treatment

Lifestyle and Supportive Measures

Smoking cessation is the cornerstone of managing emphysema, as continued tobacco use accelerates lung function decline and increases mortality risk. Interventions such as nicotine replacement therapy, behavioral counseling, and pharmacologically supported programs are recommended to facilitate quitting, with evidence showing that cessation reduces total mortality by approximately 30-50% in patients with chronic obstructive pulmonary disease (COPD), of which emphysema is a primary component.[168] Early cessation after diagnosis yields the greatest benefits, slowing disease progression and decreasing the frequency of exacerbations. Pulmonary rehabilitation programs, encompassing supervised exercise training, nutritional counseling, and education on self-management, significantly enhance quality of life and physical capacity in emphysema patients. These multidisciplinary approaches improve exercise tolerance, as measured by the 6-minute walk distance (6MWD), by approximately 50 meters on average, enabling better daily functioning and reduced dyspnea.[169] Participation in such programs, typically lasting 6-12 weeks, also fosters long-term adherence to healthy behaviors, mitigating the sedentary tendencies associated with advanced emphysema.[170] Nutritional strategies address the cachexia and weight loss prevalent in emphysema, where hyperinflation and increased energy expenditure contribute to malnutrition. High-calorie diets supplemented with adequate protein (aiming for 1.2-1.5 g/kg body weight daily) help counteract muscle wasting and support respiratory muscle function, with oral nutritional supplements shown to promote weight gain and improve exercise performance in undernourished patients.[171] Tailored intake, emphasizing energy-dense foods and possibly omega-3 fatty acids, is particularly beneficial for those with low body mass index.[172] Annual influenza vaccination and pneumococcal immunization with PCV20 or PCV21 (as per current CDC/ACIP guidelines for adults 50 years and older) are essential preventive measures to avert infections that trigger exacerbations in emphysema patients. These vaccines reduce the incidence of acute exacerbations by up to 50-70% and lower hospitalization rates for respiratory complications.[173][174] Routine administration aligns with global health recommendations for high-risk groups.[175] In patients with mild emphysema (a form of mild COPD), resting oxygen saturation (SpO2) is typically normal, ranging from 95% to 100%, similar to healthy individuals. Hypoxemia at rest is uncommon in mild cases, and supplemental oxygen is not routinely required unless desaturation occurs during exertion or in more advanced disease. Targets of 88-92% apply mainly to moderate-severe COPD with chronic hypoxemia or hypercapnia risk, not mild emphysema.[176] Long-term oxygen therapy (LTOT) is indicated for emphysema patients with severe hypoxemia, defined as a partial pressure of arterial oxygen (PaO2) below 55 mmHg or oxygen saturation ≤88% at rest. Delivered continuously (at least 15 hours daily), LTOT extends survival by 1-2 years compared to nocturnal use alone, as demonstrated in landmark trials like the Nocturnal Oxygen Therapy Trial (NOTT), which reported a 45% reduction in mortality risk with continuous therapy.[177] This intervention also alleviates symptoms and improves sleep quality, but requires careful monitoring to ensure adherence and avoid complications like oxygen toxicity.[178]

Pharmacotherapy

Pharmacotherapy for emphysema primarily targets symptom relief, improvement in lung function, and prevention of exacerbations, as there is no cure for the underlying alveolar destruction. Treatments follow guidelines for chronic obstructive pulmonary disease (COPD), of which emphysema is a key component, emphasizing stepwise escalation based on symptom severity, exacerbation history, and lung function metrics like forced expiratory volume in one second (FEV1).[89] Bronchodilators form the cornerstone of therapy, relaxing airway smooth muscle to alleviate dyspnea and enhance airflow. Long-acting beta-2 agonists (LABAs), such as salmeterol and indacaterol, improve FEV1 by approximately 100-150 mL and reduce breathlessness, with evidence from randomized controlled trials showing sustained benefits over 12-24 weeks compared to placebo.[179] Long-acting muscarinic antagonists (LAMAs), including tiotropium and umeclidinium, provide similar FEV1 gains of 120-200 mL and are particularly effective in reducing exacerbation frequency by up to 20-25% versus short-acting options, due to their longer duration of action.[89][180] Dual LABA/LAMA combinations, such as indacaterol/glycopyrronium, yield additive FEV1 improvements of 150-250 mL and superior symptom control over monotherapy, making them first-line for moderate-to-severe emphysema with persistent symptoms.[181] Inhaled corticosteroids (ICS) are reserved for patients with frequent exacerbations (two or more per year) or those with an asthma-COPD overlap, often combined with LABAs to mitigate risks like pneumonia. Fluticasone propionate, for instance, in fixed-dose combinations with salmeterol, reduces moderate-to-severe exacerbation rates by about 25% compared to bronchodilator monotherapy, with benefits most pronounced in patients with blood eosinophil counts above 300 cells/μL.[182] This effect stems from anti-inflammatory actions that stabilize airways, though ICS do not alter long-term FEV1 decline and are not recommended for monotherapy in pure emphysema phenotypes; de-escalation is advised based on eosinophil counts or adverse events per 2025 guidelines.[89] Phosphodiesterase-4 (PDE4) inhibitors like roflumilast are indicated for severe emphysema (FEV1 <50% predicted) with chronic bronchitis and a history of exacerbations despite optimal bronchodilator therapy. Administered orally once daily, roflumilast reduces moderate-to-severe exacerbations by 15-20% and provides modest FEV1 improvements of 50-100 mL when added to existing regimens, targeting inflammation in the lower airways.[89] Its use is limited by side effects such as weight loss and gastrointestinal upset, restricting it to select high-risk patients. For emphysema due to alpha-1 antitrypsin (A1AT) deficiency, augmentation therapy involves weekly intravenous infusions of purified A1AT (e.g., 60 mg/kg) to raise serum levels and protect lung tissue from proteolytic damage. Meta-analyses of randomized trials demonstrate that this slows FEV1 decline by approximately 20-23% (or 10-15 mL/year) compared to non-augmented controls, particularly in patients with moderate airflow obstruction (FEV1 30-65% predicted).[183] Therapy is lifelong and monitored via A1AT levels, but it does not reverse existing emphysema. Mucolytics, such as N-acetylcysteine (NAC), play a limited adjunctive role in emphysema management, primarily for patients with viscous sputum and frequent exacerbations not controlled by bronchodilators. High-dose oral NAC (600 mg twice daily) modestly reduces exacerbation frequency by 20-25% and improves health status in non-ICS users, possibly through antioxidant effects that thin mucus and reduce oxidative stress.[89] Evidence is inconsistent across populations, and routine use is not endorsed outside chronic bronchitis phenotypes. Biologics targeting type 2 inflammation are recommended in the 2025 GOLD guidelines for patients with eosinophilic COPD and frequent exacerbations despite optimized bronchodilators. Dupilumab, a monoclonal antibody blocking IL-4 and IL-13, reduces moderate-to-severe exacerbations by about 30% and improves lung function in phase III trials (BOREAS and NOTUS), with approvals in the US (2024), EU, Japan (2025), Canada (2025), and other regions for adults with inadequately controlled COPD and type 2 inflammation (e.g., blood eosinophils ≥300 cells/μL).[184][185] Mepolizumab, an anti-IL-5 monoclonal antibody, is approved in the US (May 2025) as add-on maintenance for eosinophilic COPD, reducing exacerbations by 20-25% in trials.[186][187]

Surgical Options

Surgical options are considered for patients with advanced emphysema who remain symptomatic despite optimal medical therapy and pulmonary rehabilitation. These procedures aim to improve lung function, exercise capacity, and quality of life by addressing hyperinflation and irreversible tissue damage. The primary surgical interventions include lung volume reduction surgery (LVRS), bullectomy, and lung transplantation, each with specific indications, eligibility criteria, and associated risks.[188] Lung volume reduction surgery (LVRS) involves the resection of 20-30% of the most damaged lung tissue, typically from the upper lobes, to allow healthier lung regions to expand and function more effectively. The National Emphysema Treatment Trial (NETT) demonstrated that LVRS provides a survival benefit in patients with upper-lobe predominant emphysema and low exercise capacity, with a 5-year survival rate of 70% compared to 60% with medical therapy alone.[189] Eligibility for LVRS requires severe emphysema confirmed by pulmonary function tests (e.g., FEV1 20-35% predicted), heterogeneous distribution on CT imaging, completion of a pulmonary rehabilitation program, and abstinence from smoking for at least 4 months. Contraindications include severe comorbidities such as unstable coronary artery disease, severe pulmonary hypertension, or FEV1 below 20% predicted without upper-lobe predominance. Complications occur in up to 90% of cases, with prolonged air leaks (lasting >7 days) in 10-20% and perioperative mortality of 5-10%, particularly higher (up to 16%) in high-risk groups like those with low exercise capacity and diffuse emphysema.[188][190][191] Bullectomy is indicated for the removal of giant bullae—large air-filled sacs occupying more than 30% of the hemithorax—that compress adjacent functional lung tissue and contribute to dyspnea. This procedure, often performed via video-assisted thoracoscopic surgery, can improve FEV1 by 15-20% postoperatively by allowing re-expansion of compressed parenchyma.[192] Candidates for bullectomy typically have a single dominant bulla with preserved underlying lung function (FEV1 >40% predicted) and no diffuse severe emphysema. Severe comorbidities or multiple small bullae are contraindications. Complications include prolonged air leaks in 10-20% of cases and perioperative mortality of approximately 5%, with overall functional improvements sustained for at least 1-3 years in most patients.[192] Lung transplantation is reserved for end-stage emphysema patients with FEV1 <20% predicted, severe hypercapnia, or recurrent exacerbations despite maximal therapy. Single or bilateral lung transplantation replaces diseased lungs with donor organs, offering the most definitive treatment for eligible candidates who are non-smokers, have completed rehabilitation, and lack major comorbidities like active malignancy or severe frailty. The 5-year survival rate is 50-60%, with median survival around 5 years, though bilateral procedures may yield slightly better long-term outcomes (up to 66% at 5 years).[193] Post-transplant complications include primary graft dysfunction (up to 20%), chronic rejection (bronchiolitis obliterans syndrome in 50% by 5 years), and perioperative mortality of 5-10%, emphasizing the need for lifelong immunosuppression and close monitoring.[194]

Bronchoscopic Interventions

Bronchoscopic interventions represent minimally invasive alternatives to surgical lung volume reduction for patients with severe emphysema, targeting hyperinflated lung regions to improve respiratory mechanics and symptoms. These procedures, performed via flexible bronchoscopy under sedation or general anesthesia, aim to reduce lung volume by blocking airflow to damaged areas or inducing targeted tissue contraction, thereby alleviating hyperinflation—a key pathophysiological feature where residual volume exceeds 175% of predicted. Approved options include endobronchial valves, lung volume reduction coils, and thermal vapor ablation, each suited to specific emphysema patterns and patient profiles.[195] Endobronchial valves, such as the Zephyr valves, are one-way devices deployed in the airways of hyperinflated lobes to achieve atelectasis by preventing air entry while allowing exhalation. In the LIBERATE trial, a multicenter randomized controlled study of 190 patients with heterogeneous emphysema, Zephyr valve treatment resulted in a mean FEV1 improvement of approximately 10-15% at 12 months compared to standard care, alongside gains in exercise tolerance and quality of life. These valves are particularly effective in patients with complete interlobar fissure integrity, confirmed by imaging or collateral ventilation testing, to ensure targeted lobe isolation.[196] Lung volume reduction coils, made from nitinol—a shape-memory alloy—are bronchoscopically placed in subsegmental airways of heterogeneous emphysema regions to mechanically compress damaged parenchyma, reducing hyperinflation and enhancing elastic recoil. Clinical trials, including the RENEW study involving 316 patients, demonstrated modest efficacy with FEV1 increases of 7-11% and residual volume reductions of 0.31-0.71 L at 12 months, particularly benefiting those with upper-lobe predominant disease. Coils are advantageous for patients ineligible for valves due to collateral ventilation but require multiple deployments (typically 10-12 per lobe) across sessions to achieve volume reduction.[197] Thermal vapor ablation, using the InterVapor system, involves delivering heated water vapor (at 75°C) to selected emphysematous segments, provoking an inflammatory response that leads to absorption atelectasis, fibrosis, and subsequent volume reduction. In a multicenter trial of 44 patients with upper-lobe heterogeneous emphysema, this technique yielded a 48% lobar volume decrease (approximately 716 mL) at 6 months, with FEV1 improvements of about 141 mL and enhanced 6-minute walk distance, effects sustained to 12 months in responders. The procedure targets lobes with high emphysema destruction scores and is limited to 1-2 segments per session to manage post-treatment inflammation.[198] Eligibility for these interventions emphasizes heterogeneous emphysema distribution, confirmed by high-resolution CT, and significant hyperinflation with residual volume greater than 175% predicted, alongside FEV1 between 15-45% predicted and adequate exercise capacity. Patients must lack active smoking, severe comorbidities, or diffuse disease, with pre-procedure assessments including perfusion scintigraphy to identify target lobes. These criteria ensure benefits outweigh risks in carefully selected individuals with post-bronchodilator FEV1 responsiveness limited by trapped air.[195] Overall outcomes include reduced COPD exacerbations—observed in up to 40% fewer events annually with valves in real-world data—and improved dyspnea scores, though benefits vary by technique and patient adherence to pulmonary rehabilitation. Complications, while generally manageable on an outpatient basis, encompass pneumothorax (5-10% incidence across methods, higher at 26% with valves requiring chest tube drainage in most cases), transient exacerbations, and pneumonia, with serious adverse events occurring in 20-30% within 30 days. Long-term follow-up from pivotal trials indicates sustained functional gains for 1-5 years in responders, positioning these interventions as bridges to lung transplantation or standalone therapy for non-surgical candidates.[199][196][197]

Emerging Therapies

Emerging therapies for emphysema focus on regenerative and targeted biological approaches to address the underlying alveolar destruction and inflammation, particularly in patients with alpha-1 antitrypsin (A1AT) deficiency or advanced disease where standard treatments fall short. Stem cell therapy, particularly using mesenchymal stem cells (MSCs), aims to regenerate damaged alveoli through their immunomodulatory and reparative properties. Preclinical models have demonstrated that MSCs can reduce inflammation, promote tissue repair, and improve lung function in elastase-induced emphysema.[200] Phase I and II clinical trials have shown MSCs to be generally safe, with some evidence of modest improvements in forced expiratory volume in one second (FEV1), such as a reported increase of approximately 100-150 mL in select cohorts of severe chronic obstructive pulmonary disease (COPD) patients with emphysematous features after intravenous or endobronchial administration.[201] However, larger phase II studies, including those evaluating multiple doses over 52 weeks, have not consistently demonstrated significant FEV1 gains or sustained benefits, highlighting the need for optimized dosing and patient selection.[202] Ongoing phase III trials, such as the RESPIRE protocol using adipose-derived MSCs, are assessing long-term efficacy in improving FEV1 and quality of life in moderate-to-severe emphysema.[203] Anti-inflammatory biologics target specific cytokines to modulate protease-antiprotease imbalances implicated in emphysema progression. Inhibitors of interleukin-13 (IL-13), such as lebrikizumab and tralokinumab, have been investigated for their role in reducing mucus hypersecretion and airway remodeling, with phase II trials in COPD showing potential reductions in exacerbation rates among patients with elevated IL-13 levels.[204] Dupilumab, a monoclonal antibody blocking the IL-4 and IL-13 shared receptor, has demonstrated significant benefits in phase III trials (BOREAS and NOTUS) for COPD patients with type 2 inflammation, including a 30% reduction in moderate-to-severe exacerbations and improved lung function. In contrast, tumor necrosis factor (TNF) inhibitors like infliximab and etanercept have largely failed to show clinical efficacy in emphysema or COPD trials, with phase II and III studies reporting no significant impact on exacerbations or lung function despite preclinical evidence of TNF's role in inflammation; safety concerns, including increased infection risk, have limited further development.[205][206] Itepekimab (anti-IL-33) in the AERIFY program showed mixed results, meeting the primary endpoint for exacerbation reduction in AERIFY-1 (27% reduction at week 52 in former smokers with COPD) but not in AERIFY-2. The RESOLUTE trial for benralizumab (anti-IL-5R) did not meet its primary endpoint for exacerbation reduction in September 2025. Depemokimab (anti-IL-5) is under evaluation in ongoing phase III trials (e.g., ENDURA-2, initiated 2025) for ultra-long-acting effects on lung function in type 2-high COPD.[207][208][209] Gene therapy represents a promising avenue for A1AT-deficient emphysema, where adeno-associated virus (AAV) vectors deliver functional A1AT genes to restore antiprotease levels and halt lung destruction. Early phase I/II trials using intramuscular or aerosolized AAV vectors, such as AAV1 and AAV2 serotypes, have achieved stable transgene expression with serum A1AT levels reaching 10-20% of normal for up to a year, alongside evidence of slowed emphysema progression on computed tomography.[210] A phase I trial initiated in 2025 with AAV8-hAAT(AVL), an oxidation-resistant variant (NCT06996756), is evaluating safety and efficacy in adults with A1AT deficiency and emphysema, focusing on durable A1AT production without immune rejection.[211] Challenges include vector immunogenicity and transient expression, but intrapleural delivery approaches in preclinical and early human studies show potential for higher lung-specific A1AT levels.[212] Retinoids, such as all-trans retinoic acid (ATRA), seek to promote alveolar repair by activating retinoic acid receptors that regulate lung development and matrix remodeling. Animal models of emphysema have shown ATRA to induce septal tissue formation and reduce airspace enlargement.[213] Early human trials, including a phase II pilot study administering oral ATRA (1-2 mg/kg/day) for 12 weeks, reported tolerability but no significant radiographic or functional improvements in emphysema patients.[214] The FORTE phase II trial similarly found no overall benefit in lung density or FEV1, leading to a failed phase III effort with ATRA; however, selective retinoid agonists like palovarotene and gamma-selective variants are under investigation in preclinical and early-phase studies as of 2025 to enhance specificity and avoid systemic toxicity.[215][216] As of November 2025, the landscape for emphysema therapies includes phase III trials for biologics like depemokimab, with persistent challenges involving selecting appropriate endpoints beyond FEV1, such as imaging-based emphysema progression and patient-reported outcomes, to better capture disease modification in heterogeneous populations.[217]

Prognosis and Prevention

Prognostic Factors

Prognostic factors in emphysema play a crucial role in predicting patient outcomes and guiding therapeutic decisions, with disease severity, comorbidities, phenotypic characteristics, and response to interventions serving as key determinants. Overall, the median survival after diagnosis of emphysema ranges from 5 to 10 years, varying by stage and management, though this can be substantially extended through early intervention.[218] Disease severity, often assessed via forced expiratory volume in one second (FEV1), is a primary predictor of survival; patients with FEV1 less than 30% of predicted value experience approximately halved 5-year survival rates compared to those with milder obstruction, reflecting advanced airflow limitation and hyperinflation.[219] The Global Initiative for Chronic Obstructive Lung Disease (GOLD) staging system, which incorporates FEV1, further stratifies risk in emphysema as a COPD subtype.[220] The 2025 GOLD report emphasizes cardiovascular comorbidities, including pulmonary hypertension and coronary artery disease, as significant modifiers of prognosis, increasing mortality risk in advanced emphysema.[221] Comorbidities significantly influence prognosis, with the BODE index—a composite score integrating body mass index (BMI), degree of obstruction (FEV1), dyspnea (via modified Medical Research Council scale), and exercise capacity (6-minute walk test)—providing a robust predictive tool. A BODE score greater than 7 indicates poor prognosis, correlating with heightened mortality risk from respiratory failure or exacerbations, as validated in large cohorts where such scores predicted up to 80% mortality within 4 years.[222] Emphysema phenotype also affects outcomes, with upper-lobe predominant centrilobular emphysema generally conferring a better prognosis than diffuse panlobular forms due to less extensive alveolar destruction and better preservation of lower lobe function. Panlobular emphysema, often linked to alpha-1 antitrypsin deficiency, is associated with more severe airflow obstruction, greater symptom burden, and reduced exercise capacity.[223] Response to therapy, particularly lung volume reduction surgery (LVRS), offers prognostic insight; patients with upper-lobe predominant emphysema and low baseline exercise capacity derive significant survival benefits post-LVRS, including reduced mortality and improved quality of life, as demonstrated in the National Emphysema Treatment Trial.[189] Emerging biologic therapies, such as mepolizumab approved in 2025 for eosinophilic COPD phenotypes, may further improve prognosis by reducing exacerbation frequency and preserving lung function in responsive patients.[224] Smoking cessation markedly improves prognosis in emphysema patients, potentially increasing survival by up to 50% compared to continued smoking by slowing disease progression and reducing exacerbation frequency.[225]

Prevention Strategies

Public health initiatives targeting tobacco use have significantly contributed to the prevention of emphysema, a primary component of chronic obstructive pulmonary disease (COPD). Anti-smoking campaigns and policies, including taxation, advertising bans, and smoke-free legislation, have led to substantial declines in smoking prevalence, which in turn has reduced COPD incidence rates since 2000. For instance, population-based tobacco control strategies have demonstrated the potential to lower overall COPD prevalence by addressing the leading modifiable risk factor.[226][227] Occupational safety measures play a crucial role in preventing emphysema among workers exposed to respiratory irritants. Effective dust control through local exhaust ventilation systems and the use of personal protective equipment (PPE), such as respirators, can minimize inhalation of harmful particles like silica or coal dust in industries including mining, construction, and manufacturing. Regulatory standards from agencies like the Occupational Safety and Health Administration (OSHA) emphasize engineering controls and appropriate PPE to reduce occupational contributions to COPD, which account for a notable population-attributable fraction of cases.[228][229][230][231] Genetic screening for alpha-1 antitrypsin (A1AT) deficiency is recommended for individuals with a family history of early-onset emphysema or COPD, enabling early intervention to mitigate progression. Testing identifies those with low A1AT levels, a genetic risk factor present in about 1% of COPD cases, allowing for targeted avoidance of smoking and environmental exposures. Clinical guidelines advocate familial screening to facilitate preventive measures, such as augmentation therapy in deficient individuals, which can preserve lung function when initiated early.[46][118][232][54] Environmental regulations aimed at improving air quality are essential for emphysema prevention, particularly in reducing exposure to ambient pollutants and indoor biomass smoke. Policies limiting particulate matter and nitrogen oxides from industrial and vehicular sources have been shown to lower COPD exacerbation risks and support overall lung health. Programs replacing traditional biomass stoves with cleaner alternatives, such as chimney-equipped or efficient models, have demonstrated substantial reductions in COPD risk in high-exposure populations, like those in rural areas reliant on solid fuels. The 2025 GOLD report highlights the growing impact of climate change, including more frequent extreme weather events, on COPD exacerbations, recommending preventive strategies such as enhanced disaster preparedness and air quality monitoring to mitigate risks for vulnerable populations.[233][234][235][221] Early detection through spirometry screening is a key strategy for at-risk populations, such as smokers over 40 years old, to identify preclinical airflow obstruction before symptomatic emphysema develops. Routine spirometry can detect reduced forced expiratory volume in one second (FEV1) in asymptomatic individuals, enabling smoking cessation and other interventions to halt progression. Studies support targeted screening in this demographic, where undiagnosed obstruction prevalence can reach 20-25%, allowing for timely preventive actions.[236][237][238]

History

Early Descriptions

The earliest recorded observations of respiratory conditions resembling emphysema date back to ancient times, where symptoms of breathlessness were noted without specific anatomical correlation to lung pathology. Around 450 BCE, Hippocrates, often regarded as the father of medicine, described a condition termed "asthma," derived from the Greek word for panting or labored breathing, characterized by episodes of severe dyspnea and wheezing triggered by environmental factors such as dust or cold air.[239] This portrayal emphasized breathlessness as a primary symptom but did not yet distinguish it from other forms of respiratory distress, framing it more as a symptomatic state than a distinct disease entity.[240] The term "emphysema" itself emerged in the 17th century, marking the first explicit reference to lung overinflation as a pathological finding. In 1679, Swiss physician Théophile Bonet, in his work Sepulchretum, provided the inaugural description of "voluminous lungs" observed during autopsies, coining the term "emphysema" from the Greek en (in) and phýsa (to inflate or blow), to denote the abnormal inflation and enlargement of lung tissue.[241] Bonet's observations were based on post-mortem examinations and highlighted the lungs' failure to collapse properly, though clinical symptoms were not yet systematically linked to this finding.[242] By the early 19th century, more detailed clinical and pathological characterizations solidified emphysema as a recognizable entity, distinct from other respiratory ailments like bronchitis. In 1821, French physician René Laënnec, inventor of the stethoscope, detailed emphysema in his Traité de l'auscultation médiate, describing autopsied lungs as pale, mottled, hyperinflated, and containing bullae—large air-filled spaces—while noting their poor collapsibility and association with progressive dyspnea, particularly in older men who were often smokers.[241] Laënnec observed that this condition manifested as chronic, worsening shortness of breath in middle-aged and elderly males, with post-mortem examinations revealing marked lung overdistension, and he explicitly differentiated emphysema from bronchitis, viewing it as a separate pathological process involving alveolar destruction rather than inflammatory mucus production.[243] These insights, drawn from clinical auscultation and autopsy correlations, established emphysema as a progressive disorder of lung structure, predating modern understandings of chronic obstructive pulmonary disease.[244]

Key Milestones in Understanding

In the 1950s, epidemiological research established a strong causal link between cigarette smoking and emphysema, building on earlier observations of chronic respiratory disease in smokers. Pioneering work by Richard Doll and Austin Bradford Hill, through their prospective cohort studies initiated in the early 1950s, demonstrated that heavy smoking significantly increased mortality from lung diseases, including emphysema as a component of chronic bronchitis and obstructive lung disease.[245] Concurrently, Noel C. Oswald and colleagues provided a detailed pathological description of centriacinar emphysema in 1953, identifying it as a predominant form in smokers characterized by dilation of respiratory bronchioles in the central lung lobule, which advanced understanding of the disease's morphological subtypes.[245] The 1960s marked pivotal advances in the genetic and biochemical underpinnings of emphysema. In 1963, Carl-Bertil Laurell discovered alpha-1 antitrypsin deficiency (A1ATD) while analyzing serum protein patterns, revealing low levels of this protease inhibitor in patients with unexplained emphysema, thus linking genetic factors to early-onset disease.[241] In 1964, Paul Gross proposed the protease-antiprotease imbalance theory, experimentally inducing emphysema-like changes in animal lungs using papain, an enzyme that degrades elastin, thereby suggesting that unchecked proteolytic activity from neutrophil elastase could destroy alveolar walls in susceptible individuals.[241] During the 1970s, diagnostic and therapeutic foundations for emphysema evolved with the introduction of computed tomography (CT) imaging and early explorations of lung volume reduction. The first clinical CT scanners, developed by Godfrey Hounsfield in 1971, enabled non-invasive visualization of lung parenchyma by the mid-1970s, allowing detection of emphysematous changes like bullae and hyperinflation that were previously obscured on plain radiographs.[246] Precursors to the National Emphysema Treatment Trial (NETT) emerged through initial studies on surgical interventions, including reports of unilateral lung volume reduction procedures that improved ventilation-perfusion matching in select patients with severe emphysema, setting the stage for randomized evaluations.[190] The 2000s solidified evidence-based treatments and refined etiological models. The NETT, a multicenter randomized controlled trial published in 2003, enrolled 1,218 patients with severe emphysema and found that lung volume reduction surgery (LVRS) improved exercise capacity and quality of life compared to medical therapy alone, particularly in those with upper-lobe predominant disease and low baseline exercise tolerance, though it increased short-term mortality risk in high-risk subgroups.[189] This trial's results led to Medicare coverage for LVRS in qualified patients. Additionally, studies in the 2000s confirmed the protease-antiprotease imbalance as a core mechanism, with biochemical analyses showing elevated elastase activity and reduced inhibitors like A1AT in emphysematous lungs of smokers, validating Gross's earlier hypothesis through human tissue and biomarker data.[247] In the 2010s and 2020s, genomic and minimally invasive approaches advanced emphysema research. Genome-wide association studies (GWAS) identified novel susceptibility loci, such as variants near HHIP and IREB2 genes associated with emphysema severity and distribution on CT scans, enhancing risk prediction beyond A1ATD and informing personalized medicine.[248] The U.S. Food and Drug Administration approved the Zephyr endobronchial valve in 2018 for bronchoscopic lung volume reduction in severe emphysema patients with no collateral ventilation, based on the LIBERATE trial demonstrating significant improvements in lung function and six-minute walk distance.[249] Ongoing stem cell trials, including phase I/II studies using mesenchymal stem cells to modulate inflammation and promote alveolar repair, show preliminary safety and modest efficacy in reducing emphysema progression, with larger trials in progress to assess long-term outcomes.[200] As of 2024, an early clinical trial in China involving pulmonary stem cell transplants in 20 COPD patients suggested improvements in lung function, highlighting continued progress in regenerative approaches.[250]

References

  1. Emphysema - Symptoms and causes - Mayo Clinic
  2. Emphysema - StatPearls - NCBI Bookshelf
  3. Emphysema | American Lung Association
  4. Pathogenesis of hyperinflation in chronic obstructive pulmonary ...
  5. What Is COPD? - NHLBI - NIH
  6. Emphysema: Video, Causes, & Meaning - Osmosis
  7. COPD / Emphysema | UCSF Pulmonary, Critical Care, Allergy and ...
  8. COPD Trends Brief - Prevalence | American Lung Association
  9. Associations between emphysema-like lung on CT and ... - PubMed
  10. Epidemiology of COPD | European Respiratory Society
  11. Chronic obstructive pulmonary disease (COPD)
  12. International variation in the prevalence of COPD (the BOLD Study)
  13. Decreased COPD prevalence in Sweden after decades of decrease ...
  14. Cellular and Molecular Mechanisms of Alveolar Destruction in ...
  15. Role of Proteases in Chronic Obstructive Pulmonary Disease - PMC
  16. Oxidative Stress in Chronic Obstructive Pulmonary Disease - PMC
  17. https://doi.org/10.1164/rccm.200506-850OC
  18. Inflammation and Immune Response in COPD: Where Do We Stand?
  19. https://doi.org/10.1155/2013/413735
  20. Alveolar epithelial and endothelial cell apoptosis in emphysema - NIH
  21. https://doi.org/10.1165/rcmb.2002-0090OC
  22. Molecular pathogenesis of emphysema - PMC - NIH
  23. https://doi.org/10.1172/JCI11344
  24. Cellular and Connective Tissue Changes in Alveolar Septal Walls in ...
  25. Imaging of pulmonary emphysema: A pictorial review - PMC
  26. Capillary structure in elastase-induced emphysema - PMC - NIH
  27. Lung volume reduction for severe emphysema: do we need a ... - NIH
  28. Hypoxemia in patients with COPD: cause, effects, and disease ...
  29. Diffusing capacity in chronic obstructive pulmonary disease ...
  30. Pulmonary function testing in COPD: looking beyond the curtain of ...
  31. Pulmonary Diseases - How Tobacco Smoke Causes Disease - NCBI
  32. Chemicals in Tobacco Products and Your Health - FDA
  33. Chemistry and Toxicology of Cigarette Smoke and Biomarkers of ...
  34. Oxidative stress and redox regulation of lung inflammation in COPD
  35. Mechanisms of cigarette smoke-induced COPD: insights from ...
  36. Neutrophil Elastase Contributes to Cigarette Smoke-Induced ... - NIH
  37. Effects of smoking on disease risk among South Korean adults
  38. Secondhand smoke exposure and the risk of COPD
  39. 50-Year Trends in Smoking-Related Mortality in the United States
  40. Achievements in Public Health, 1900-1999: Tobacco Use - CDC
  41. Smoking reduction and the rate of decline in FEV 1 - ERS Publications
  42. Alpha1-Antitrypsin (AAT) Deficiency - Medscape Reference
  43. Alpha-1 Antitrypsin Deficiency - StatPearls - NCBI Bookshelf - NIH
  44. Alpha-1 antitrypsin deficiency: MedlinePlus Genetics
  45. Genes and COPD - PMC - NIH
  46. Mechanisms of emphysema in α1-antitrypsin deficiency: molecular ...
  47. American Journal of Respiratory and Critical Care Medicine
  48. Genetics of COPD and Emphysema - PMC - NIH
  49. Association Between TNF-α-308, +489, −238 Polymorphism, and ...
  50. polygenic risk scores in population-based and case-control cohorts
  51. Alpha-1 Antitrypsin Deficiency Clinical Practice Guidelines
  52. Pathogenesis and management of emphysema in people with HIV
  53. Post-tuberculosis lung disease and chronic obstructive pulmonary ...
  54. Rheumatoid arthritis-associated lung disease - PMC - PubMed Central
  55. Radiation-Induced Lung Injury—Current Perspectives and ... - NIH
  56. Panlobular pulmonary emphysema caused by i.v. injection of ...
  57. Congenital Lobar Emphysema - StatPearls - NCBI Bookshelf - NIH
  58. GOLD in Practice: Chronic Obstructive Pulmonary Disease ...
  59. COPD exacerbations: defining their cause and prevention - PMC
  60. Prevent a COPD Exacerbation or Flare Up
  61. Global Initiative for Chronic Obstructive Lung Disease 2023 Report
  62. Pulmonary hypertension and chronic cor pulmonale in COPD - PMC
  63. Cor Pulmonale - StatPearls - NCBI Bookshelf
  64. “Cor pulmonale parvus” in chronic obstructive pulmonary disease ...
  65. Cachexia in chronic obstructive pulmonary disease - PubMed Central
  66. Factors contributing to muscle wasting and dysfunction in COPD ...
  67. Inflammation and Skeletal Muscle Wasting During Cachexia - PMC
  68. COPD and osteoporosis: links, risks, and treatment challenges - NIH
  69. Osteoporosis in Asthma and COPD - PMC - NIH
  70. Fracture prevention in COPD patients; a clinical 5-step approach
  71. Impact of fatigue in patients with chronic obstructive pulmonary ... - NIH
  72. Evaluation of psychological and physiological predictors of fatigue in ...
  73. Depression in COPD – management and quality of life considerations
  74. Anxiety and depression—Important psychological comorbidities of ...
  75. Management of cardiovascular comorbidities in chronic obstructive ...
  76. Defining the relationship between COPD and CVD - NIH
  77. Prevalence and impact of diabetes, hypertension, and ... - NIH
  78. Comorbidities in Chronic Obstructive Pulmonary Disease - PMC - NIH
  79. Comorbid Heart Disease in Patients with COPD is Associated with ...
  80. Emphysema - Diagnosis and treatment - Mayo Clinic
  81. Advances in imaging for lung emphysema - PMC - PubMed Central
  82. Emphysema quantification using chest CT: influence of radiation ...
  83. Pulmonary Function Tests - StatPearls - NCBI Bookshelf - NIH
  84. Spirometry Quick Guide - GOLD
  85. Pulmonary function testing in COPD: looking beyond the curtain of ...
  86. Pulmonary Function Test - Physiopedia
  87. Oxygen desaturation during the six-minute walk test in COPD patients
  88. Prognostic Value of Desaturation during a 6-Minute Walk Test in ...
  89. Changes in Forced Expiratory Volume in 1 Second over Time in COPD
  90. Lung function decline in COPD - PMC - NIH
  91. Decline in FEV1 in Relation to Incident Chronic Obstructive ...
  92. Distinguishing among asthma, chronic bronchitis, and emphysema
  93. Heart failure and chronic obstructive pulmonary disease - NIH
  94. Centrilobular pulmonary emphysema | Radiology Reference Article
  95. Emphysema: Background, Pathophysiology, Etiology
  96. Pulmonary Emphysema Subtypes on Computed Tomography in ...
  97. Paraseptal Emphysema: From the Periphery of the Lobule to the ...
  98. Bullous Emphysema - StatPearls - NCBI Bookshelf
  99. Bullous Disease of the Lung | Thoracic Key
  100. Emphysema - Radiology Key
  101. Computed Tomography of Contemporary Occupational Lung Disease
  102. The Pathology of Chronic Obstructive Pulmonary Disease: Progress ...
  103. Full article: Phenotypes of Chronic Obstructive Pulmonary Disease
  104. A morphologic study of the airway structure abnormalities in patients ...
  105. Emphysema Imaging: Practice Essentials, Radiography, Computed ...
  106. Imaging of Emphysema: A Comprehensive Review - IntechOpen
  107. Lung Emphysema - an overview | ScienceDirect Topics
  108. Alpha-1 Antitrypsin Deficiency - GeneReviews® - NCBI Bookshelf
  109. Alpha-1 antitrypsin deficiency: an update on clinical aspects of ... - NIH
  110. Alpha-1 Antitrypsin Deficiency: Phenotypes and Quality of Life
  111. Smoking, lung function, and alpha 1-antitrypsin deficiency - PubMed
  112. Lung disease in never-smokers with severe α1-antitrypsin deficiency
  113. Alpha-1-Antitrypsin Deficiency Targeted Testing and Augmentation ...
  114. Alpha-1 antitrypsin deficiency: An underrecognized, treatable cause ...
  115. Decline in FEV1 related to smoking status in individuals with severe ...
  116. Prevalence of emphysema in people living with human ...
  117. Interactions between HIV infection and chronic obstructive ...
  118. Recent Advances in HIV-Associated Chronic Lung Disease Clinical ...
  119. Increased Risk of Radiographic Emphysema in HIV Is Associated ...
  120. Activation-induced Cell Death Drives Profound Lung CD4+ T ... - NIH
  121. COPD in People with HIV: Epidemiology, Pathogenesis ...
  122. A Low Peripheral Blood CD4/CD8 Ratio Is Associated with ... - NIH
  123. Will expanded ART use reduce the burden of HIV-associated ...
  124. Pulmonary Disease in HIV-Infected Adults in the Era of Antiretroviral ...
  125. HIV-associated Obstructive Lung Diseases - PMC - NIH
  126. Influence of Impaired Diffusing Capacity and Sleep-disordered ...
  127. Pulmonary Effects of IV Injection of Crushed Oral Tablets: “Excipient ...
  128. Recreational Drug–induced Cardiopulmonary Injury | RadioGraphics
  129. Severe precocious emphysema in intravenous methylphenidate ...
  130. https://erj.ersjournals.com/content/26/4/586
  131. Syndrome of Combined Pulmonary Fibrosis and Emphysema
  132. Combined Pulmonary Fibrosis and Emphysema: When Scylla ... - NIH
  133. Combined Pulmonary Fibrosis and Emphysema (CPFE) Clinical ...
  134. Swyer-James-MacLeod Syndrome - StatPearls - NCBI Bookshelf - NIH
  135. Spectrum of manifestations of Swyer-James-MacLeod syndrome
  136. Swyer–James–MacLeod syndrome—a rare diagnosis presented ...
  137. Congenital lobar emphysema: diagnosis and treatment options - NIH
  138. [Polyalveolosis: pathogenesis of congenital lobar emphysema?]
  139. Managing Congenital Lobar Overinflation Associated with ...
  140. Congenital lobar emphysema in bilateral lung lobes: a case report
  141. Two further cases supporting nonsurgical management in ... - PubMed
  142. Chronic obstructive pulmonary disease c 2: Pathology and biochemistry of emphysema - PMC
  143. Emphysema - Lung - Pathology Outlines
  144. 16 Lungs | Radiology Key
  145. Compensatory Emphysema - MalaCards
  146. Emphysema in asymptomatic smokers: Quantitative CT evaluation in ...
  147. Pulmonary emphysema | Radiology Reference Article
  148. Geriatric Chest Imaging: When and How to Image the Elderly Lung ...
  149. Pneumothorax in patients with COPD and emphysema receiving ...
  150. The risk of secondary spontaneous pneumothorax in patients with ...
  151. Pneumonia in Patients with Chronic Obstructive Pulmonary Disease
  152. Immune Dysfunction in Patients with Chronic Obstructive Pulmonary ...
  153. Acute exacerbations of chronic obstructive pulmonary disease
  154. Frequency and Severity of Exacerbations of COPD Associated ... - NIH
  155. Pulmonary Hypertension Secondary to COPD - PubMed Central - NIH
  156. Treatment of respiratory failure in COPD - PMC - PubMed Central
  157. Development and Relevance of Hypercapnia in COPD - PMC
  158. Osteoporosis in COPD patients: Risk factors and pulmonary ... - NIH
  159. Chronic obstructive pulmonary disease and atherosclerosis
  160. Sarcopenia and cachexia: the adaptations of negative regulators of ...
  161. Associations between depression and anxiety index and frequency ...
  162. Effect of Emphysema on Lung Cancer Risk in Smokers - NIH
  163. Improved patient outcome with smoking cessation: when is it too late?
  164. Comprehensive pulmonary rehabilitation according to severity of ...
  165. Pulmonary Rehabilitation Improves Outcomes in Chronic ... - NIH
  166. Nutritional support in chronic obstructive pulmonary disease (COPD)
  167. Targeted medical nutrition for cachexia in chronic obstructive ...
  168. Prevalence of influenza and pneumococcal vaccination in chronic ...
  169. Efficacy of Influenza and Pneumococcal Vaccination in Preventing ...
  170. Oxygen therapy for COPD - PMC - PubMed Central
  171. Long-term Oxygen Treatment in Chronic Obstructive Pulmonary ...
  172. [PDF] 2023 GOLD Pocket Guide
  173. Chronic Obstructive Pulmonary Disease (COPD) Treatment ...
  174. Treatment with LABA versus LAMA for stable COPD: a systematic ...
  175. Dual LABA/LAMA Therapy versus LABA or LAMA Monotherapy for ...
  176. Rational use of inhaled corticosteroids for the treatment of COPD
  177. Augmentation Therapy for α1 Antitrypsin Deficiency: A Meta-Analysis
  178. Lung Volume Reduction Surgery - StatPearls - NCBI - NIH
  179. lung volume reduction surgery (LVRS) - Henry Ford Health
  180. A Randomized Trial Comparing Lung-Volume–Reduction Surgery ...
  181. The National Emphysema Treatment Trial (NETT) | Part II
  182. Patients at High Risk of Death after Lung-Volume–Reduction Surgery
  183. Bullectomy for symptomatic or complicated giant lung bullae - PubMed
  184. Survival benefit of lung transplantation compared with medical ...
  185. Lung transplantation for emphysema - Inci
  186. Lung transplantation for emphysema - PMC - NIH
  187. Patient Selection for Bronchoscopic Lung Volume Reduction - PMC
  188. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial ...
  189. Lung volume reduction with endobronchial coils for patients ... - NIH
  190. Technology update: bronchoscopic thermal vapor ablation for ... - NIH
  191. Endobronchial lung volume reduction with valves reduces ...
  192. Stem cell therapies for chronic obstructive pulmonary disease
  193. Mesenchymal Stem Cell Administration in Patients with Chronic ...
  194. Stem Cell Therapy for COPD: Where are we?
  195. A Phase III Randomized, Multicenter Trial: RESPIRE Protocol
  196. Novel Anti-Inflammatory Approaches to COPD - PMC
  197. Dupilumab for COPD with Type 2 Inflammation Indicated by ...
  198. Emphysema Market Analysis Reveals Promising Growth ...
  199. Unexpected Failure of Anti–Tumor Necrosis Factor Therapy in ...
  200. TNFα antagonists for acute exacerbations of COPD - PubMed
  201. [PDF] The Role of Gene Therapy as an Emerging Treatment Strategy for ...
  202. https://clinicaltrials.gov/study/NCT06996756
  203. Intrapleural Gene Therapy for Alpha-1 Antitrypsin Deficiency
  204. A pilot study of all-trans-retinoic acid for the treatment of ... - PubMed
  205. https://www.atsjournals.org/doi/pdf/10.1164/ajrccm.165.5.2106123
  206. Randomised controlled trial for emphysema with a selective agonist ...
  207. Post-COPD: Can Emphysema Be Repaired? - ATS Journals
  208. Press Release: Itepekimab met the primary endpoint in one of two ...
  209. Depemokimab for COPD: Phase 3 Clinical Trials Now Recruiting
  210. Update on the RESOLUTE Phase III trial for FASENRA in chronic ...
  211. Emerging Therapeutics in COPD: Mapping Innovation to Treatable ...
  212. Understanding Emphysema Life Expectancy: A Comprehensive Guide
  213. Finding the Best Thresholds of FEV 1 and Dyspnea to Predict 5-Year ...
  214. Prognosis in End-Stage COPD | Palliative Care Network of Wisconsin
  215. The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise ...
  216. Panlobular emphysema is associated with COPD disease severity
  217. Smoking Status and COPD – Symptoms and Prognosis
  218. Chronic Obstructive Pulmonary Disease and Smoking Status - CDC
  219. Trends in the prevalence and incidence of chronic obstructive ... - NIH
  220. [PDF] Recommended Preventative and Control Measures to - OSHA
  221. More Stringent OSHA Standards Highlight PPE For Silica Dust
  222. How to protect workers from COPD: Overview - HSE
  223. Occupational COPD—The most under‐recognized ... - NIH
  224. Screening and Familial Testing of Patients for α1-Antitrypsin ...
  225. Air pollution and COPD: GOLD 2023 committee report
  226. Improvement in household stoves and risk of chronic obstructive ...
  227. Biomass Fuels and Respiratory Diseases | A Review of the Evidence
  228. Screening for and early detection of chronic obstructive pulmonary ...
  229. Diagnosis and early detection of COPD using spirometry - PMC - NIH
  230. SCREENING OF SMOKERS BY SPIROMETRY FOR EARLY ...
  231. The Clinical Definitions of Asthma - PMC - NIH
  232. Asthma History - News-Medical
  233. The history of COPD - PMC - PubMed Central
  234. History of Chronic Obstructive Pulmonary Disease - News-Medical
  235. History of COPD: 1600s to the Present - Healthline
  236. Understanding Early COPD - PMC - PubMed Central - NIH
  237. Early History of Chronic Obstructive Pulmonary Disease 1808–1980
  238. Chronic obstructive pulmonary disease past, present and future - PMC
  239. Does Protease–Antiprotease Imbalance Explain Chronic Obstructive ...
  240. Genome-Wide Study of Percent Emphysema on Computed ...
  241. FDA Approves Zephyr Endobronchial Valve for Treating Severe ...
  242. British Thoracic Society Guideline for oxygen use in adults in healthcare and emergency settings
  243. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2025 Report
  244. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Pocket Guide 2025
  245. How Common Is Airflow Limitation in Patients With Emphysema on CT Scan
  246. How Common Is Airflow Limitation in Patients With Emphysema on CT Scan of the Chest?
User Avatar
No comments yet.